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INTRODUCTION
Malignancies are the second most frequent cause of death in children in the Nether-
lands. Every year approximately 500-600 children aged 0-18 years are diagnosed 
with cancer 1. Survival rates of children with malignancies have increased tremendously, 
particularly in the last decennium. The survival rate of children with acute lymphatic 
leukemia (ALL) for example, has risen to almost 85% 2. One of the reasons for the 
increase in survival has been stepwise improvement in combination chemotherapy. With 
the increased survival, more attention is now being paid to the unwanted side effects 
of the treatment. A number of chemotherapeutic agents used in the treatment of child-
hood malignancies have side effects that may lead to decreased motor performance. 
Especially the use of vincristine is mentioned as a cause of problems during, and also 
after completion of chemotherapy.
Vincristine
Vincristine (VCR) has been used widely in anticancer therapy for almost forty years 3. It is 
used more frequently in pediatric patients than in adults. This may be due to the higher 
efficacy in childhood malignancies and to a better tolerance of children to relatively 
high doses 3. Cytotoxic drugs interfere with the synthesis or function of DNA, resulting 
in necrosis of cells or in apoptosis (cell death). As with most anticancer drugs VCR is 
active in a specific phase of the cell cycle, the metaphase of the mitotic process 3. Dur-
ing mitosis the microtubular network disappears and the spindle apparatus necessary 
for partitioning chromosomes is formed 4. Vincristine damages the microtubuli of the 
mitotic spindle in the cell nucleus, causing failure of the chromosomes to segregate, 
thus arresting cell proliferation which results in apoptosis 3. However, the toxic effect of 
VCR also occurs in axonal microtubuli. Axonal microtubuli enable materials necessary 
for the maintenance of structural and functional integrity of the axon and the axonal 
terminal, to be transported along the axon 5. When damage to the microtubuli occurs 
axonal transport is reduced and sometimes even obstructed, causing a degeneration 
which clinically results in peripheral neuropathy, with the most distal parts of the axon 
first affected (‘dying-back neuropathy’) 6. Axonal demyelinisation has been considered a 
secondary effect 7,8 although others have since suggested that it may in fact be primary 
9. The neurotoxic effect of VCR is cumulative and thought to increase with higher doses 
per administration, shorter intervals between administrations and higher cumulative dose, 
but inter-patient variability in response to treatment is large 10,11. Vincristine is one of the 
key drugs in the treatment of ALL, B non-Hodgkin lymphoma (NHL), Wilms’ tumor (WT) 
and malignant mesenchymal tumors (MMT). The number of VCR administrations, dose, 
maximum dose and cumulative dose vary markedly in these treatment protocols. In view 
of the fact that ALL, WT, B-NHL and MMT represent approximately 45% of all childhood 
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malignancies, a substantial number of children can be considered at risk for developing 
peripheral neuropathy (Figure 1)1.
Peripheral neuropathy
Peripheral neuropathy is the most frequent dose-limiting toxicity of VCR 12,13. VCR treat-
ment causes a symmetrical sensorimotor neuropathy which first presents with depressed 
ankle jerks and paraesthesias, followed by muscle weakness 6. Peripheral neuropathy 
can manifest itself in various ways. The symptoms reported first, as early as week 1 of 
treatment, are diminished or absent tendon reflexes of ankle and knee. Many children 
also experience reduced muscle power, most noticeably in the foot dorsiflexors and 
sometimes in the hands. Gait disturbance can be seen from the third week of treatment 
onwards. Sensory changes such as paresthesias, reduced joint position sense and re-
duced light touch sensation have also been reported 14.
Several studies have reported the prevalence of peripheral neuropathy in patients treated 
with VCR. Figures vary, depending on dosage and on the outcome parameters used. 
Decreased ankle tendon reflexes occur in 57%-100% of patients, paraesthesias in 46%-
57% and weakness in 23%-36% 7,15-18.
Clinical signs of neuropathy do not necessarily lead to alterations in chemotherapy. 
However, treatment with VCR may be discontinued if neurotoxicity starts affecting ambu-
lation. When children develop peripheral neuropathy as a side effect of VCR treatment, 
 
Figure 1/1  Prevalence of childhood malignancies in the Netherlands  
 
Figure 1 Prevalence of malignancies of children aged 0-18 years in the Netherlands.
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the reduction in muscle strength puts them at risk for losing motor ability. Children with 
reduced strength of the foot dorsiflexors also have an increased risk for developing a 
plantigrade contracture of the ankle joint 19.
Many of the clinical signs of vincristine neuropathies are reversible once treatment is 
completed, with paresthesias being the most readily reversible followed by motor and 
other sensory deficits 14. Complete recovery of neuropathy following cessation of VCR 
treatment has been reported in a study of adult patients 20. However, some contradic-
tory data were supplied by a study of adult patients showing neurological signs and 
symptoms > 6 years after cessation of chemotherapy 20. In the short term, interference 
with axonal transport leads to distal axonal degeneration. In the long term it may result in 
neuronal death as the cell is separated from its growth factors 21. Vincristine neuropathy is 
considered reversible unless the degenerative process has reached the nerve cell 3. This 
raises the question whether some children treated with VCR may not fully recover but will 
experience impairment of motor performance as a late effect of treatment.
Treatment with vincristine and motor performance
Several authors have reported impaired motor performance in 30-100% of children 
treated for ALL as long as 2-7 years after completion of treatment 22-25. However, these 
studies had limitations. Some treatment protocols also included cranial radiation in ad-
dition to chemotherapy 22-24. Another study used the Gross Motor Function Measure to 
measure motor performance, which is a test developed specifically for children with 
cerebral palsy and not suitable for children with ALL 26.
Patients who receive VCR often experience cramps and difficulty in writing 14,27,28. Follow-
up studies have been published in children treated for ALL 25,29. Vincristine neuropathy 
causes weakness in the dorsiflexors of the foot, which puts children at risk for developing 
contractures of the ankle joint. Reduced passive ankle dorsiflexion was shown in long-
term survivors of ALL compared to healthy controls matched for age and gender. Whether 
this resulted in impaired motor performance was not reported 19.
So far, only studies investigating children treated for ALL have been published. As men-
tioned before, VCR is also used in the treatment of children with B-NHL, WT and MMT, 
but no data are available on children in these patient groups.
Treatment with other drugs and motor performance
Although VCR is the most frequently mentioned drug causing motor impairment, there are 
other chemotherapeutic agents that may also affect motor performance.
Besides VCR, treatment protocols for ALL, B-NHL and WT contain a considerable amount 
of corticosteroids (prednisone and/or dexamethasone) which may cause myopathy 
leading to weakness of proximal musculature of upper and lower limbs 12. In addition 
corticosteroids are known to cause avascular necrosis predominantly of weight bearing 
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joints, causing pain and loss of function 30. Five year cumulative incidence of avascular 
necrosis in children treated for ALL is 5%-7% 31,32. The highest frequency is observed in 
adolescents. Osteoporosis is another side effect which, although unlikely to affect motor 
performance directly, is associated with an increased risk of fractures 33.
Cytosine arabinoside (Ara-C), which is used in the treatment of ALL and B-NHL may cause 
cerebral or cerebellar dysfunction but this is rare in children 13. Intrathecal methotrexate 
(MTX) administered in the ALL and B-NHL protocols can cause transient paraplegia 13.
Other factors related to motor performance
Impairment of motor performance is not dependent on muscle strength and coordination 
only. The International Classification of Functioning, Disability and Health (ICF) shows 
the relationships between various aspects of disorder/disease and level of functioning 
34. The ICF describes the effects of a disorder/disease in terms of impairment in body 
function and structure, impairment in activity and impairment in participation (Figure 
2). Environmental and personal factors (e.g. age, motivation, self-image) are also of 
importance as they can contribute to the level of functioning in positive or negative way. 
The ICF model and its’ application to polyneuropathy was used as a framework for the 
research presented in this thesis.
 
 
Figure 1/2  The ICF model applied to peripheral neuropathy
Disorder or disease
peripheral neuropathy 
impairment
decreased muscle strength 
hand held dynamometer 
loss of joint mobility 
goniometer 
activity restriction
impaired motor performance 
movement ABC 
impaired handwriting 
BHK 
amily activities 
decreased participation in school activities 
decreased participation in sports 
 
external factors
environment
personal factors
altered perception of self 
-CBSK 
Figure 2 The International Classification of Functioning, Disability and Health (ICF) model showing the 
relationships between various aspects of disorder/disease and level of functioning. Bold text = ICF ter-
minology; regular text = impairments associated with peripheral neuropathy; italics = instruments used to 
measure impairments
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Measuring motor performance in children
Motor performance in children varies with age. Therefore any standardized test for 
motor performance has to contain age related motor tasks. Motor ability in children is 
affected by experience and standardized motor tasks should resemble activities of every 
day life. Thirdly, age-related reference values should be available in order to compare a 
child’s ability to the ability of healthy peers. Two tests of motor performance meet these 
criteria: the Bayley Scales of Infant Development Second Edition (BSID-II) and the Move-
ment Assessment Battery for Children (m-ABC) 35-37. The BISD-II is used to measure motor 
performance of children aged 1-42 months. The number of items the child manages to 
perform is calculated. The movement-ABC consists of a series of eight standardized tasks 
covering hand function, ball skills and balance skills. Age-related norms exist for children 
aged 4-12 years.
Writing is a also a motor skill. Research has shown that difficulty writing is not necessar-
ily associated with an impairment in motor performance in general 38. Measuring hand 
writing ability therefore requires a specialised test. The ‘Beknopte Beoordelingsmethode 
voor Kinderhandschriften’ (Concise Assessment Scale for Children’s Handwriting) was 
developed for Dutch children attending grade 4 (aged 7-9 years) and 5 (aged 8-10 
years) of regular primary education 39.
The ICF model shows how ‘personal factors’ contribute to level of functioning. It is there-
fore also important to know the child’s own opinion on whether he considers his motor 
performance to be impaired. An instrument which measures self-perceived motor per-
formance is the motor supplement of the ‘Competentie BelevingsSchaal voor Kinderen’ 
(m-CBSK) which was developed for Dutch children aged 8-12 years 40.
In order to understand why motor performance becomes impaired, impairment of ‘func-
tion and structures’ such as muscle strength and joint mobility need to be investigated. 
Muscle strength is measured using a hand held dynamometer. Joint mobility can be 
recorded using a goniometer. Figure 2 shows the instruments used to investigate impair-
ments placed in the context of the ICF model.
Effect of intervention
Neuronal damage due to the toxic effect of vincristine will only be affected by withdrawal 
of the drug. However, it may be possible to reduce the impact of polyneuropathy on 
motor performance. Some types of intervention have already been investigated. A posi-
tive effect of preventative education and stretching and strengthening exercises during 
treatment for ALL on passive ankle dorsiflexion compared to historical controls has been 
demonstrated 41. Whether this also improved functional ability is unclear. In another study 
in children receiving treatment for ALL the effect of a four month period of physical therapy 
improved ankle mobility and knee extension strength but had no effect on functional out-
come i.e. there was no significant improvement in ability to run or to walk the stairs 42.
Chapter 1
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Genetic variation
Response to vincristine treatment can vary considerably. Polymorphisms in genes involved 
in the metabolisation of vincristine are a likely cause. Vincristine belongs to the group 
of vinca-alkaloid drugs metabolised by the cytochrome P450 system in the liver 43. 
Isoforms of this system expressed in humans are CYP3A4 and CYP3A5. Polymorphisms 
of CYP3A4 exist but are rare, whereas polymorphisms of CYP3A5 are relatively com-
mon 44-46. The multi drug resistance (MDR-1 or ABCB1) gene is also involved in the 
pharmacokinetics of VCR. Upregulation of the MDR-1 gene encoding for P-glycoprotein 
(P-gp), an efflux pump, results in a decrease in intracellular concentration of VCR and an 
increase in biliary clearance 47,48. Genetic variation in the microtubule-associated protein 
tau (MAPT) gene may influence VCR effects at the tissue level. MAPT promotes the assem-
bly and stabilisation of microtubules, which form a target for VCR as described above. 
MAPT abnormalities have been linked to a number of neurodegenerative disorders e.g. 
Parkinson’s disease, progressive supranuclear palsy, and Alzheimer’s disease 49-51.
As vincristine neuropathy can give rise to motor problems, a link may exist between the 
presence of polymorphisms in these genes and the level of motor performance of children 
treated with VCR as part of their chemotherapy.
Outline of the thesis
The occurrence of motor problems in children during treatment for ALL has often been 
reported and has been attributed to polyneuropathy, a side effect of VCR. It has been 
assumed that VCR neuropathy is reversible and when the drug is withdrawn previous 
function recovers. However, no studies were available on the long-term motor outcome in 
children treated for ALL, or in children treated with VCR for other childhood malignancies. 
Therefore the aim of the work described in this thesis was to study the long-term effects of 
VCR containing chemotherapy on motor performance and handwriting in children and to 
investigate which other factors were of influence.
In Chapter 2 we investigate motor performance in children who were treated for ALL, 
WT, B-NHL or MMT and had completed treatment for at least one year. The effect of 
cumulative dose of VCR and use of corticosteroids on motor performance is analysed.
Handwriting often deteriorates in children who receive VCR, which is frequently noted 
by parents and teachers. Vincristine causes a polyneuropathy that can affect peripheral 
hand muscles and therefore hand function. We hypothesised that handwriting of chil-
dren treated with VCR would still differ from healthy peers in the long-term. Chapter 3 
describes a study investigating this hypothesis by means of a standardised writing test. 
Polyneuropathy results in weakness of the peripheral muscles of hands and feet. We 
were interested to know whether any muscle weakness would still be present in the long 
term and whether this would affect motor performance. Also, dorsiflexors of the foot 
are often affected in children with VCR neuropathy leading to inadequately lifting the 
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foot whilst walking. This can result in reduced passive dorsiflexion of the ankle that may 
persist even when muscle strength improves. In Chapter 4 we report on a study investi-
gating peripheral strength of hands and feet and passive ankle dorsiflexion. Results of 
children who completed VCR containing chemotherapy are compared to healthy peers. 
The relationship of strength and passive ankle mobility with motor performance is also 
investigated. Earlier in this introduction it was suggested that motor performance might 
be affected by a number of factors. Children who have been treated with chemotherapy 
may perceive their motor performance differently for various reasons. If they do not rate 
their performance very highly this may have an adverse effect on undertaking physical 
activity or participating in sports. If they rate their motor performance as adequate it 
could raise the question whether impaired motor performance requires intervention or 
not. In Chapter 5 we investigate the hypothesis that self perceived motor competence 
of children treated with VCR containing chemotherapy differs from their healthy peers. 
We also examined the relationship between the rated motor performance and the actual 
motor performance level to establish whether they rate themselves appropriately.
Large interindividual differences in the adverse effect of VCR treatment in children exist. 
We hypothesised that his may be due to genetic variation in drug metabolising (CYP3A5) 
or VCR-toxicity related (MDR-1, MAPT) genes. In the study described in Chapter 6 the 
presence of polymorphisms of these genes is in children with ALL is studied in relation to 
motor performance.
Although impaired motor performance and passive ankle dorsiflexion are known side 
effects of VCR there is little information on whether these side effects can be prevented.
One study shows an effect of stretching exercises on passive ankle dorsiflexion mobility 
and another on strengthening exercises on muscle power of the knee extensors, but 
functional outcome is not measured. In Chapter 7 we report on a randomised trial in 
children with ALL comparing the effect of an intervention programme with standard care 
on motor performance and bone density. Chapter 8 contains a summary of the research 
presented in this thesis. In Chapter 9 the results are discussed and future prospects 
outlined. Chapter 10 provides a summary in Dutch.
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ABSTRACT
Background
Impaired performance on motor tasks in children treated for acute lymphoblastic leuke-
mia (ALL) after completion of treatment is often attributed to vincristine. Whether motor 
problems persist in other children who receive different cumulative doses of vincristine is 
not known. The aim of the present study was to determine the extent of motor problems in 
children with ALL, Wilms’ tumor (WT), B non-Hodgkin lymphoma (B-NHL) and malignant 
mesenchymal tumors (MMT) and whether these were related to vincristine dose.
Methods
In 127 children who completed treatment at least one year and were aged 4-12 years, 
motor performance was measured by the Movement Assessment Battery for Children 
(m-ABC).
Results
The m-ABC scores of the total study group were significantly lower than those of the nor-
mal population (p<0.001). There were no differences in scores between children with 
ALL, WT, B-NHL and MMT. There were also no differences between children with ALL 
who had or had not received pulses of VCR and steroids during maintenance therapy. All 
groups showed large variability in scores. Scores were not significantly different between 
children who had received low (0-20 mg/m²) intermediate (20-40 mg/m²) or high (> 
40 mg/m²) cumulative doses of vincristine. Cumulative doses of corticosteroids and 
methotrexate did not affect scores, nor did age at diagnosis and time since completion 
of therapy.
Conclusions
Although motor performance was impaired in all patient groups, no relationship was 
found between motor performance and cumulative dose of vincristine or other drugs, age 
and follow-up time. Future studies have to address whether for instance polymorphisms in 
drug metabolizing genes or drug target genes explain the large variability in long-term 
motor outcome of children with cancer.
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INTRODUCTION
A number of chemotherapeutic agents used in the treatment of childhood malignan-
cies have side effects that might lead to decreased motor performance. The occurrence 
of motor problems is often attributed to vincristine, which is successfully used in the 
treatment of acute lymphoblastic leukemia (ALL). Vincristine causes the development of 
polyneuropathy which may lead to pain 1, sensory loss and a decrease in muscle power 
in upper and lower extremities 2. Several authors found motor problems in 30% to 100% 
of children with ALL, 2 to 7 years after treatment had been completed 3-8. However, 
all these studies had limitations because children had received cranial radiotherapy in 
addition to chemotherapy 3-5, numbers were small 6, ankle mobility was used as the only 
outcome measure 7, or a motor test for children with cerebral palsy was used to assess 
motor performance 8.
Some ALL protocols contain vincristine /steroid pulses during maintenance therapy 
whereas other protocols do not, leading to large differences in cumulative vincristine and 
steroid doses (see Table I). Whether motor problems differ depending on the use of pulses 
is unknown. Vincristine is also used to treat Wilms’ tumor (WT), B non-Hodgkin lymphoma 
(B-NHL) and malignant mesenchymal tumors (MMT). Limited data have been reported 
on motor problems in these patient groups. Two studies in adult lymphoma patients have 
been published. One study describes motor problems during chemotherapy treatment in 
all 27 patients studied 9. Furthermore, overall motor weakness was described in 20% of 
patients with a median follow-up time of 11 months after completion of therapy 10. So far, 
no data have been published on motor problems in children treated with chemotherapy 
for malignancies other than ALL.
The aim of the present study was to determine 1) the extent of motor problems in children 
with ALL, Wilms’ tumor (WT), B non-Hodgkin lymphoma (B-NHL) and malignant mesen-
chymal tumors (MMT), 2) whether these motor problems differed between patient groups 
and 3) and whether this was dependent on administered cumulative vincristine dose and 
the use of vincristine / steroid pulses during maintenance therapy.
Table I Vincristine schedules
ALL-8 ALL-9 WT NHL MMT
number of doses vincristine
dose in mg/m²
cumulative dose in mg/m²
duration of vincristine treatment in weeks
8-10
1.5
12-15
22-23
31-34
2.0
62-68
103
8-24
1.5
12-36
10-33
3-7
2.0
6-14
4-24
10-13
1.5
15-19.5
15-24
ALL-8 = acute lymphoblastic leukemia treated with DCOG protocol 8, ALL-9 = acute lymphoblastic leukemia 
treated with DCOG protocol 9, WT = Wilms’ tumor, NHL = non Hodgkin lymphoma, MMT = malignant 
mesenchymal tumor, mg/m² = milligrams per square meter body surface.
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MATERIAL AND METhODS
Patients
The study was conducted at the pediatric oncology departments of the Erasmus MC 
Sophia Children’s Hospital and the Emma Children’s Hospital AMC in the Netherlands. 
Approval of the Medical Ethical Committees in both hospitals was obtained. Informed 
consent was obtained from the parents of all participating children.
Inclusion criteria:
- age 4-12 years at time of testing (because the motor test which was used, is vali-
dated for this age category only)
- diagnosed with ALL, WT, B-NHL or MMT
- at least one year after completion of therapy
Exclusion criteria:
- a solid tumor whereby the location of the tumor itself could contribute to motor 
problems, such as a bone tumor of the femur or tibia for example.
- attending special education, as cognitive impairment is known to influence results of 
the m-ABC motor test.
Treatment
Children with ALL were treated according to the treatment protocols of the Dutch Child-
hood Oncology Group: the BFM based ALL-811 that does not contain VCR/steroid pulses 
during maintenance and protocol ALL-9, which is almost identical to the previously used 
protocol ALL-6 and does contain VCR/steroid pulses during maintenance therapy 12. 
Protocols of the Societé Internationale d’Oncologie Pédiatrique were used to treat chil-
dren with WT and MMT 13,14. Children with B-NHL were treated with DCOG-NHL-94 or 
LMB-96 protocol; these two protocols are very similar. Cumulative vincristine doses were 
obtained for each child by medical record extraction.
Assessment of motor problems
Motor performance was measured using the Dutch version of the Movement Assessment 
Battery for Children (m-ABC) 15,16. The m-ABC consists of a series of eight standardized 
tasks divided in three subsections: hand function, ball skills and balance skills. The tasks 
vary with age and are designed to resemble every day activities of children. The total 
score of the m-ABC summarizes performance on all eight tasks and is transformed by 
age-related norms into a percentile score. A score below the 5th percentile is indicative 
of a motor problem, between 5th and 15th percentile is borderline and higher than the 
15th percentile is normal. In addition to the total score the child’s performance on each 
of the subsections can also be expressed as either below or above the 15th percentile. 
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Validity of the m-ABC to test motor ability in children aged 4-12 years has been shown 
before 17.
Physical assessment
Height and weight of the children at time of assessing motor performance were mea-
sured. Measurements of height and weight at the onset of chemotherapy were obtained 
from the medical records.
Sensory loss in hands and feet was assessed by clinically examining perception of 
pain, light touch sensation, vibration and joint position sense. A structured interview was 
conducted with parents and children to establish the extent of symptoms such as pain in 
upper and/or lower extremities, activity level and participation in sports.
The same senior pediatric physiotherapist performed assessments of all children.
Statistics
The SPPS statistical package (version 10.1) was used to analyze the data. Mean group 
differences in m-ABC percentile scores were analyzed with t-tests and one-way ANOVA. 
Paired t-tests were used to analyze differences in height and weight SD scores at the 
onset of chemotherapy and at follow-up. Pearson’s correlation coefficient was calculated 
to evaluate the relationship between weight for height SD scores and percentile scores. 
Analysis of covariance was performed to determine the effect of age at diagnosis and 
time since completion of treatment on percentile scores, adjusted for patient groups.
RESULTS
Patients
A total number of 142 children were invited to participate in the study. The parents of 
13 children did not respond. One child was excluded because he was diagnosed with 
Gilles de la Tourette syndrome. The results of the remaining 128 children, 61% boys and 
39% girls, were used for analysis. Of these, 16 children had been treated with ALL-8 
protocol, 41 children with ALL-9, 43 children had been treated for WT, 12 children for 
B-NHL and 16 children for MMT. Mean age at time of follow-up was 8.1 years (range 
4.1-12.8) and mean time since completion of treatment was 3.2 years (range 1.0-7.1). 
Characteristics of the patient groups are shown in Table II.
Motor performance
Percentile scores on the m-ABC of the total study group were significantly lower than 
scores of the normal population, whereby 65% of the children in the study group scored 
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below the 50th percentile (p<0.001), 25% of the children scored below the 15th per-
centile (p<0.001), and 11% scored below the 5th percentile (p<0.001).
There were no significant differences in percentile scores between children treated with 
ALL-8, ALL-9, WT, MMT and B-NHL protocols (see figure 1). All groups showed large 
variability in m-ABC scores, with median percentile scores of 26.5 (ALL-8), 35.0 (ALL-9), 
40.0 (WT), 25.0 (B-NHL) and 44.0 (MMT).
In order to investigate specifically the effect of vincristine treatment, children were grouped 
according to cumulative dose of vincristine received. The first group had received < 20 
Table II Characteristics of patient groups
ALL-8
(n=16)
ALL-9
(n=41)
WT
(n=43)
NHL
(n=12)
MMT
(n=16)
total group
(n=128)
boys-
girls (%)
9 (56%)
7 (44%)
23 (56%)
18 (44%)
24 (56%)
19 (44%)
11 (92%)
 1 (8%)
11 (69%)
 5 (31%)
78 (61%)
50 (39%)
mean age at testing in years 
± sd
9.7 ± 1.4 8.0 ± 2.2 7.7 ± 2.4 8.7 ± 1.7 7.7 ± 2.2 8.1 ± 2.2
mean age at diagnosis in 
years ± sd
3.1 ± 1.1 3.8 ± 2.2 3.3 ± 2.1 5.6 ± 1.6 3.8 ± 2.1 3.7 ± 2.1
mean time since stop 
chemotherapy in years ± sd
4.7 ± 1.3 2.0 ± 0.6 3.8 ± 1.5 2.8 ± 1.1 3.3 ± 1.3 3.2 ± 1.5
ALL-8 = acute lymphoblastic leukemia treated with DCOG protocol 8, ALL-9 = acute lymphoblastic leukemia 
treated with DCOG protocol 9, WT = Wilms’ tumor, NHL = non Hodgkin lymphoma, MMT = malignant 
mesenchymal tumor, sd = standard deviation.
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Figure 2/1  Motor performance after treatment for different types of childhood cancer 
 
Figure 1 Relationship between percentile scores on m-ABC motor performance test after treatment for: ALL 
= acute lymphoblastic leukemia, WT = Wilms’ tumor, NHL = non-Hodgkin lymphoma, MMT = malignant 
mesenchymal tumor. The horizontal bars represent the median values.
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mg/m² (low), the second group 20-40 mg/ m² (intermediate) and the third group > 40 
mg/ m² (high). No significant differences in m-ABC percentile scores between the low, 
intermediate and high vincristine groups were found (one way ANOVA, see figure 2).
There was also no significant difference in percentile scores of children treated with 
ALL-8 (without VCR/steroid pulses during maintenance) and ALL-9 regimen (with pulses). 
As an effect of cumulative vincristine dose could not be demonstrated, the effect of other 
drugs was analyzed. Two groups were formed: a group treated with corticosteroids, 
consisting of children who had been treated with ALL-8, ALL-9 or B-NHL protocols, and a 
non-corticosteroid group with children treated with WT or MMT protocols. A two-sample 
t-test showed no difference in percentile scores between these two groups.
All but one of the children treated with corticosteroids received MTX and it was con-
firmed that there was also no significant difference in scores between MTX and non-MTX 
groups.
Analysis of covariance showed that age at diagnosis and time since completion of 
treatment had no significant effect on percentile scores, corrected for patient groups. The 
effect of male or female sex on percentile scores was not significant.
Physical assessment
We analyzed whether weight for height at time of follow up affected percentile scores: 
there was a weak but significant correlation of rp = -0.25 (p=0.005). The correlation 
between weight gain during treatment and percentile scores was not significant (rp = 
-0.12).
 
Figure 2/2 Motor performance of children after treatment with different doses of  
vincristine  
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Figure 2 Relationship between percentile scores on m-ABC motor performance test after treatment with low 
(20 mg/m²) intermediate (20-40 mg/m²) and high (> 40 mg/m²) cumulative doses of vincristine. The 
horizontal bars represent the median values.
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Sensory loss was found in small numbers of children only: diminished light touch sensa-
tion in 10%, loss of joint position sense in 2% and one child had diminished vibration 
sense. It should be noted that 10% of the children could not be tested because they were 
too young to fully understand the procedure.
A structured interview was completed for all children whereby 5% reported paraesthesia 
and 23% still regularly experienced pain. Neither paraesthesia nor sensory loss had 
an effect on m-ABC scores, but regularly experiencing pain was significantly related to 
lower percentile scores (p=0.034). Physical education at school was attended by 91% 
of the children and 70% participated in sports after school, which is average in the 
Netherlands 18.
DISCUSSION
This study shows that motor performance is impaired in children who were treated for 
ALL, WT, B-NHL and MMT tested 3.2 (range 1.0-7.1) years after completion of treat-
ment. These results are in accordance with those of Reinders-Messelink 6 who also used 
the m-ABC to measure motor performance and found that 33% of children treated for ALL 
scored below the 15th percentile. The current study demonstrates that motor problems do 
not only occur in children with ALL. Performance was also impaired in patients treated 
for WT, B-NHL or MMT, but no differences between groups were found. This implies 
that a negative effect on motor outcome as a result of that childhood cancer and/or its 
treatment is a more frequently occurring phenomenon.
All these children had received vincristine as part of their chemotherapy, which is known 
to cause neuropathy. The relationship between vincristine dose and motor performance 
has not been reported before, but it was expected that scores on the motor test of these 
patient groups would be dependent on the cumulative vincristine dose. For example 
children with high cumulative doses of vincristine, such as those treated for ALL with 
VCR/steroid pulses during maintenance were expected to show poorer scores than ALL 
children treated with maintenance without VCR/steroid pulses. Surprisingly the data did 
not support this. There was large interindividual variability in scores in all patient groups, 
irrespective of cumulative vincristine dose. Cumulative vincristine dose was therefore not 
the determining factor in motor performance and these findings suggest that even a low 
dose can cause impairment. Although we did not study children who received no vincris-
tine at all, children who received a minimal amount were included in the study. The lack 
of correlation between cumulative vincristine dose and motor performance supports the 
policy of not reducing the dose in case of for instance a decrease of ankle dorsiflexion.
Use of other drugs was also considered. Corticosteroids can cause myopathy 19, osteo-
porosis 11 and avascular necrosis 20-22 and therefore may have a negative effect on motor 
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outcome. Corticosteroids are used in the treatment of both ALL and B-NHL, but not in 
WT and MMT. Treatment for ALL and B-NHL also includes the use of methotrexate (MTX), 
which can cause encephalopathy 19,23-25 and could adversely affect motor performance. 
However, performance was impaired to the same extent in all patient groups and not 
only in those children who had ALL or B-NHL. We therefore concluded that differences in 
scores could not be explained by use of steroids nor MTX. To the best of our knowledge 
there are no reports on other drugs used in the treatment of ALL, WT, B-NHL and MMT 
that could offer an explanation.
Motor outcome may also be influenced by age at diagnosis. It has been suggested that 
degree of neuropathy in children treated with vincristine is influenced by age, with infants 
most heavily affected 2. In the present study age at diagnosis did not affect percentile 
scores. It should be noted however that our study group did not include any infants.
As the m-ABC motor test is only suitable for children aged 4 to 12 years, older children 
were excluded from the study. Whether our results hold true for older children is therefore 
uncertain. It is known that older children more often show severe side effects of steroids 
26,27 and they might also respond differently to vincristine.
We also hypothesized that time since completion of treatment could influence motor 
outcome. It has been shown that neurotoxic signs and symptoms tend to disappear over 
time 28 and therefore motor performance could be expected to improve over time. How-
ever, time since completion of chemotherapy did not influence motor outcome, which 
suggests that some children may have irreversible damage. This is known to occur when 
the degeneration process caused by vincristine reaches the perikaryon of the peripheral 
nerves 29-32.
As in many other studies, the children in our study did significantly gain weight during 
chemotherapy treatment (data not shown). The effect of weight itself on percentile scores 
was significant but small; weight gain did not influence percentile scores.
There may be a relationship between pain, which was experienced by 23% of the chil-
dren, and poorer scores on the m-ABC. As the data on pain were collected by structured 
interview and not by a validated pain measure, the nature of the relationship between 
pain and motor performance could not be explored any further.
An explanation for variability in motor performance in all patient groups may be that
the m-ABC percentiles scores are a reflection of motor performance prior to the onset of 
illness. Being ill and having chemotherapy causes motor performance in all children to 
decrease, resulting in lower scores but with the same variability as before.
Another reason for the large variability in percentile scores in all patient groups could 
be that sensitivity to vincristine in children differs. Vincristine could have a greater impact 
in children sensitive to vincristine. Polymorphisms in vincristine metabolizing genes or 
vincristine target genes could be the underlying cause of this differential sensitivity.
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The results of our study seem to be at odds with a recently published study on 114 adults 
with lymphoma where more damage was noted after a cumulative vincristine dose of 12 
mg/m²33. However, patients in this study were adults, the last measurements were taken 
only 4 weeks after completion of treatment and the authors did not use a standardized 
test for motor performance. Results of both studies can therefore not be compared.
In conclusion, we found impaired motor performance in all patient groups (ALL, WT, 
B-NHL, MMT) but no relationship with cumulative doses of vincristine or other drugs, age 
and follow up time. At present it is not possible to predict which children are likely to 
become affected and what their motor outcome will be.
Future studies will have to address whether for instance polymorphisms in vincristine 
metabolizing genes or vincristine target genes or gene mutations leading to an increased 
tendency to (hereditary) neuropathies such as Charcot-Marie-Tooth disease 34,35, may 
identify children at increased risk of developing motor problems.
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ABSTRACT
Background
Long-term writing difficulties in children after treatment with vincristine for acute lympho-
blastic leukemia, Wilms’ tumor, B non-Hodgkin lymphoma and malignant mesenchymal 
tumors, were investigated.
Procedure
Handwriting of 33 survivors and 33 controls matched for age, sex and grade, was 
assessed with the BHK-scale. The examiner was blinded for whether a child was a case 
or a control.
Results
No significant difference in writing speed was found. Mean difference in number of 
letters produced during five minutes was 6.4 (± 67.1, range –103 to +169). No signifi-
cant difference was found in quality of writing scores; mean difference in points was 1.5 
(± 7.7, range -19 to +22). Cumulative vincristine dose, age at diagnosis or time since 
completion of treatment did not affect writing speed or quality.
Conclusion
Chemotherapy, including vincristine, does not lead to long-term problems in speed or 
quality of writing in children treated for cancer.
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INTRODUCTION
Vincristine is a chemotherapeutic agent, which is used in the treatment of a number of 
childhood malignancies. A well-known side effect of vincristine is polyneuropathy, which 
can lead to a decrease of muscle power and coordination problems in the distal part of 
upper and lower extremities. Sensory loss has also been reported 1-6.
Patients who receive vincristine often experience difficulty in writing, as is frequently 
reported by parents and teachers 7. Some patients mention cramps during writing, others 
state that the quality of their handwriting has decreased. Only one follow-up study on 
the effect of vincristine on handwriting has been published, studying children with acute 
lymphoblastic leukemia (ALL). This suggested a significant difference in quality of writing 
between 17 children who were at least two years since completion of treatment for ALL 
(range 2.3-7.9 years) and controls, using the BHK handwriting test 8. However, the 
results of the study are questionable because children were older than the guidelines for 
the BHK test stipulate.
Vincristine is also used to treat Wilms’ tumor (WT), B non-Hodgkin lymphoma (B-NHL) 
and malignant mesenchymal tumors (MMT). No data have been reported on writing 
problems in these patients groups. The aim of the present study was to determine the 
extent of long term writing problems in children treated for ALL, WT, B-NHL and MMT.
MATERIALS AND METhODS
Patients and controls
The study was conducted in the pediatric oncology departments of the Erasmus MC So-
phia Children’s Hospital and the Emma Children’s Hospital in the Netherlands. Approval 
of the Medical Ethical Committees in both hospitals was obtained.
Inclusion criteria: 1) diagnosed with ALL, WT, B-NHL or MMT; 2) at least one year after 
completion of therapy; 3) attending primary school grade 4 (7-9-years) or grade 5 (8-10 
years) at time of testing. Children performed a handwriting test individually as part of 
a larger study 9, in which hand function was also measured with the Dutch version of 
the Movement Assessment Battery for Children (m-ABC) 10,11. A large cohort of healthy 
controls performed the handwriting test, group wise in their classrooms. Out of this cohort 
33 controls were selected, who matched the survivors for primary school grade, age and 
sex. Informed consent was obtained from the parents of all participating children.
Treatment
Children with ALL were treated according to the protocols of the Dutch Childhood On-
cology Group: the BFM based ALL-8 12 that does not contain vincristine (VCR)/steroid 
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pulses during maintenance and protocol ALL-9, which is almost identical to the previously 
used protocol ALL-6 and does contain VCR/steroid pulses during maintenance 13. Both 
protocols consist of chemotherapy only and do not include cranial irradiation. Protocols 
of the Societé Internationale d’Oncologie Pédiatrique were used to treat children with 
WT and MMT 14,15. Children with B-NHL were treated with DCOG-NHL-94 or LMB-96 
protocol; these two protocols are very similar 16. Cumulative vincristine doses in the 
above mentioned treatment protocols vary, as does duration of treatment (see Table I). 
For each child in the patient group cumulative vincristine doses were obtained by medi-
cal record extraction.
Assessment of handwriting problems
Handwriting was assessed using the Concise Assessment Scale for Children’s Handwrit-
ing, known as the BHK-scale, which was developed for Dutch children attending grade 
4 (aged 7-9 years) and 5 (aged 8-10 years) of regular primary education 17. Children 
are asked to copy a standard text for five minutes at their normal speed, with their 
commonly used writing utensil. The writing paper is unlined. The standard text gradually 
increases in difficulty. The first five sentences are at grade 3 reading level.
Writing speed is calculated by counting the number of letters produced during the five 
minute period. These can be converted into age referenced decile scores. Scores in 
deciles 1- 2 are considered too slow, scores in deciles 3-10 are within the norm. The 
quality of handwriting is rated by examining the first five sentences written. The quality 
items used in the BHK-scale are listed in Table II. The first two items are measured on an 
ordinal scale (0-6 penalty points) weighted differently for children in grade 4 and 5. The 
other eleven items are yes/no items indicating for each of the five sentences whether 
an abnormality is present or not, resulting in 0-5 penalty points for each item. Total BHK 
scores range from 0 – 67 points, with a higher number of points indicating poorer quality 
of handwriting. Scores can be converted into three handwriting categories: normal (0 - 
21 points), ambiguous (22 - 28 points), or abnormal (> 28 points). Validity and reliability 
of the BHK-scale have been reported elsewhere 18.
Table I Vincristine schedules
ALL-8 ALL-9 WT B-NHL MMT
number of doses vincristine
dose in mg/m²
cumulative dose in mg/m²
duration of vincristine treatment in weeks
8-10
1.5
12-15
22-23
31-34
2.0
62-68
103
8-24
1.5
12-36
10-33
3-7
2.0
6-14
4-24
10-13
1.5
15-19.5
15-24
ALL-8 = acute lymphoblastic leukemia treated with DCOG protocol 8, ALL-9 = acute lymphoblastic leukemia 
treated with DCOG protocol 9, WT = Wilms’ tumor, NHL = non Hodgkin lymphoma, MMT = malignant 
mesenchymal tumor, mg/m² = milligrams per square meter body surface.
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In addition to performing the handwriting test, children who had been treated with 
vincristine were asked whether they had any complaints regarding their handwriting at 
the time of testing. Parents were asked whether there were any changes in their child’s 
handwriting as far as speed or legibility were concerned.
There was one examiner who rated the handwriting samples and she was kept blind to 
whether a child had a history of childhood cancer or was a healthy control. The hand-
writing samples of the whole group were presented to the examiner in random order. 
Prior to the study intra-rater reliability was determined by presenting the examiner with 
ten samples of handwriting of children in grade 4 or 5. The same samples were returned 
to the examiner again one week later, in random order and without the examiner being 
informed that they were the same handwriting samples as in the previous batch.
Statistics
The SPSS statistical package (version 10.1) was used to analyse the data. The intraclass 
correlation coefficient was calculated to measure agreement between first and second 
ratings of the ten handwriting samples. Paired t-tests were used to analyse differences 
between survivors and controls in number of letters written and in total BHK scores.
In the patient group, Pearson’s correlation coefficients were calculated to investigate 
relationships between age at time of testing, age at diagnosis, time since completion of 
treatment, cumulative vincristine dose and hand function scores measured by the m-ABC 
versus speed and quality of writing. The Mann Whitney test was used to analyse differ-
ences between children with and without hand writing complaints.
Comparison of ordinal categorical scores between survivors and controls was carried 
out with the linear-by-linear association test.
Table II Items of the BHK scale for rating quality of writing
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Large letter size
Widening of left hand margin
Poor line alignment
Insufficient word spacing
Angular connections between letters
Irregular connections between letters
Colliding letters
Inconsistent letter size
Inconsistent letter height
Distorted letters
Ambiguous letter shapes
Corrected letters
Unsteady writing trace
Items of the BHK scale (= standardized instrument for measurement of handwriting) for rating quality of 
handwriting. The first two items are measured on an ordinal scale (0-6) weighted differently for children in 
grade 4 and 5. The other 11 items are yes/no items indicating whether an abnormality is present or not 
and are applied to each of the first five sentences written.
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RESULTS
Patients
A total number of 33 survivors participated in the study, 20 boys (61%) and 13 girls 
(39%). Fifteen children (45%) attended grade 4 and 18 children (55%) attended grade 
5. Left-handedness was seen in five children (15%).
Of the 33 children, seven children had been treated with ALL-8 protocol, eight children 
with ALL-9, eleven had been treated for WT, three for MMT and four for
B-NHL. All protocols use a maximum vincristine dose, but none of the survivors reached 
the maximum. Mean age at time of follow-up was 8.6 years (range 7.3-10.2) and 
mean time since completion of treatment was 3.6 years (range 1.4-6.5). There was no 
significant difference in age between the survivors and controls; the mean age difference 
was 0.1 years. Characteristics of all participating survivors are shown in Table III.
Table III Characteristics of the patient groups
ALL-8
(n=7)
ALL-9
(n=8)
WT
(n=11)
B-NHL
(n=4)
MMT
(n=3)
boys:girls 2 : 5 5 : 3 7 : 4 3 : 1 3 : 0
mean age at testing in
years ± sd
9.0 ± 0.7 8.5 ± 0.8 8.3 ± 0.6 8.4 ± 0.9 8.7 ± 0.3
mean age at diagnosis in years 
± sd
2.6 ± 0.4 4.3 ± 0.8 3.4 ± 1.8 5.4 ± 1.1 5.0 ± 1.1
mean time since stop 
chemotherapy in years ± sd
4.4 ± 0.7 2.3 ± 0.5 4.3 ± 1.6 2.8 ± 0.6 3.2 ± 0.8
ALL-8 = acute lymphoblastic leukemia treated with DCOG protocol 8, ALL-9 = acute lymphoblastic leukemia 
treated with DCOG protocol 9, WT = Wilms’ tumor, NHL = non Hodgkin lymphoma, MMT = malignant 
mesenchymal tumor, sd = standard deviation.
Intra-rater agreement
The intra-class correlation coefficient of ratings of ten handwriting samples on the first and 
second occasion was good (0.81).
Writing speed and quality of handwriting
No significant difference was found between survivors and their paired controls in writ-
ing speed. Mean number of letters produced during five minutes by the survivors and 
controls was 135.45 and 129.03 respectively. The mean difference between survivors 
and controls was 6.4 (± 67.1, range -103 to +169) (Figure 1). Mean age referenced 
decile scores for writing speed was 5.03 in the survivor group and 5.00 in the control 
group. Mean difference in age referenced decile scores for writing speed between 
survivors and controls was 0.03 (± 4.6, range –8 to +9).
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There was also no significant difference in quality of handwriting. Mean number of 
penalty points scored by survivors and controls was 20.36 and 18.88 respectively. The 
mean difference in number of penalty points between survivors and paired controls was 
1.48 (± 7.7, range -19 to +22), see Figure 2.
 
Figure 3/1  Writing speed 
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Figure 1 Writing speed of patients who had completed treatment with vincristine for at least one year 
and paired healthy controls, matched for age, sex and school grade. Scores are obtained by counting 
the number of letters written during five minutes of copying a standard text. The patient group consisted of 
children treated for acute lymphoblastic leukemia, Wilms’ tumor, B non-Hodgkin lymphoma, or malignant 
mesenchymal tumor.
 
Figure 3/2  Quality of handwriting 
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Figure 2 Quality of writing scores on BHK scale (= standardized instrument for measurement of handwrit-
ing) of patients who had completed treatment with vincristine for at least one year and matched paired 
healthy controls. Scores are obtained by rating the first five sentences written when copying a standard text. 
Scores of 0-21 points are considered ‘normal’, 22-28 points ‘ambiguous’ and > 28 points ‘abnormal’. The 
patient group consisted of children treated for acute lymphoblastic leukemia, Wilms’ tumor, B non-Hodgkin 
lymphoma, or malignant mesenchymal tumor.
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The results of total BHK scores when converted into the categories ‘normal’, ‘ambiguous’ 
and ‘abnormal’ are shown in Table IV. There were no significant differences in distribu-
tion in these categories between survivors and controls.
In the patient group the effect of age at time of testing, age at diagnosis, time since 
completion of therapy and cumulative vincristine dose on age referenced scores of writ-
ing speed and quality of handwriting was analyzed (Table V). A moderate inverse cor-
relation between age at time of testing and age referenced scores for writing speed was 
found (rp = -0.42, p=0.02). This correlation was also inversed in the control group (rp = 
-0.15) but did not reach significance.
There was a moderate inverse correlation between time since completion of therapy 
and age referenced decile scores for writing speed (rp = -0.42, p=0.02); this was no 
longer significant after correcting for cumulative vincristine dose (rp = -0.31, p=0.09). 
There was also a moderate positive correlation between writing speed and cumulative 
vincristine dose (rp =0.36, p = 0.04), this was no longer significant after correcting for 
time since completion of therapy (rp = 0.22, p = 0.24). A significant inverse correlation 
Table IV Quality of writing category scores on the BHK scale
normal
(0-21 points)
ambiguous
(22-28 points)
abnormal
(> 28 points)
patients 18 (55%) 13 (39%) 2 (6%)
controls 23 (70%) 9 (27%) 1 (3%)
Quality of writing scores on the BHK scale (= standardized instrument for measurement of handwriting) when 
converted into the categories ‘normal’, ‘ambiguous’ and ‘abnormal’ for patients and paired healthy controls, 
matched for age, sex and school grade. The patient group consisted of children treated for acute lympho-
blastic leukemia, Wilms’ tumor, B non-Hodgkin lymphoma, or malignant mesenchymal tumor. Treatment had 
been completed for at least one year. Differences in distribution of categories between patients and controls 
were not significant (linear-by-linear association test, p=0.16).
Table V The effect of several variables on age referenced scores of writing speed and quality of handwriting 
in survivors
writing speed writing quality
age at testing rp = -0.42 (p=0.02*) rp = -0.12 (p=0.52)
age at diagnosis rp = 0.17 (p=0.34) rp = -0.16 (p=0.93)
time since completion of therapy rp = -0.42 (p=0.02*) rp = 0.01 (p=0.98)
cumulative vincristine dose rp = 0.36 (p=0.04*) rp = 0.21 (p=0.24)
The effect of age at time of testing, age at diagnosis, time since completion of therapy and cumulative 
vincristine dose on age referenced scores for writing speed and quality of handwriting in the survivor group 
(n=33). The survivor group consisted of children treated for acute lymphoblastic leukemia, Wilms’ tumor, B 
non-Hodgkin lymphoma, or malignant mesenchymal tumor. rp = Pearson’s correlation. * denotes statistical 
significance.
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was found between time since completion of therapy and cumulative vincristine dose (rp 
= -0.45, p=0.01).
As no adverse effect of vincristine was demonstrated, the role of other drugs was also 
examined. There were no significant differences in age-referenced scores for writing 
speed or in scores of writing quality between children who received methotrexate and 
those who did not, or between children who were treated with corticosteroids and those 
who were not.
In the survivor group there was no relationship between age-referenced scores for writing 
speed and total BHK score. There was also no relationship between m-ABC hand func-
tion score (data not shown) and writing speed or total BHK score.
In the survivor group nine (29%) of 31 children, or their parents, had complaints regard-
ing their handwriting. Children with and without complaints did not differ in writing 
speed, but there was a significant difference in quality of handwriting (p=0.04); children 
with complaints produced poorer scores. There was no significant difference in time 
since completion of chemotherapy between children with and without complaints.
DISCUSSION
Two main outcome parameters are important in handwriting: speed and legibility, i.e., 
quality of writing. The present study shows that there is no difference in writing speed or 
in quality of writing between children attending grade 4 and 5 who have been treated 
with vincristine and healthy matched controls.
Our results are in contrast to a study by Reinders-Messelink et al. in which a significant 
difference in quality of writing between 17 children who had been treated for ALL 
and their controls was found 8. These discordant results may be explained by the fact 
that the children in the Reinders-Messelink et al. study were asked to write as fast as 
possible, whereas the BHK guidelines stipulate to write at normal speed. It is known 
that children who have difficulty writing manage to increase their speed by ‘trading-off’ 
against accuracy. It could be that in the Reinders-Messelink et al. study children who had 
been treated with vincristine increased their writing speed but at the expense of quality, 
whereas the controls managed to increase their speed and maintain quality. Another 
explanation for the difference between survivors and controls could be that the examiner 
in the Reinders-Messelink et al. study was not blinded to the diagnosis and some bias 
favoring the control group may therefore have taken place. In addition, the quality score 
of the BHK scale is validated for children attending grade 4 and 5 only and some of the 
children who took part in their study were older than the BHK guidelines specify, which 
may have been of influence.
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Testing of the survivors in our study was carried out individually; controls were tested 
group wise in their classroom. This could introduce a bias in the results; however, there 
is no evidence to suggest that either group would have been favored or disadvantaged 
by the mode of administration of the test.
There was a weak but significant inverse relationship in the patient group between age 
at time of testing and age referenced scores for writing speed in our study. The speed-
accuracy trade-off effect may also explain these findings. The demand on speed and 
accuracy both increase with age. In order to maintain accuracy, writing speed of the 
survivors relatively remains behind. However, survivors did not significantly differ from 
their controls.
We hypothesized that writing speed should improve the greater the time since comple-
tion of therapy and the smaller the cumulative vincristine dose. In our study we found 
the opposite: a negative correlation between time since completion of therapy and 
writing speed and a positive correlation between cumulative vincristine dose and writing 
speed. There was an inverse correlation between time since completion of therapy and 
cumulative vincristine dose. Further analysis revealed however, that neither variable was 
independently associated with writing speed.
About 30% of the children treated with vincristine, or their parents, complained of changes 
in the handwriting since completion of treatment. It appears that their complaints refer to 
quality of writing as we found that children with complaints had poorer quality of writing 
than children without complaints, but there was no difference in writing speed.
In conclusion, the long-term quality of handwriting and writing speed had not deteriorated 
in children treated with chemotherapy including vincristine. Cumulative dose and age at 
time of treatment did not adversely affect writing quality or speed in the long term.
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ABSTRACT
Background
This study investigated muscle strength, passive ankle dorsiflexion and their association 
with motor performance in children after treatment for acute lymphoblastic leukemia, 
Wilms’ tumor, B-non-Hodgkin lymphoma and malignant mesenchymal tumors.
Procedure
Muscle strength was assessed with a hand-held dynamometer and ankle dorsiflexion with 
a goniometer in 92 and 64 survivors respectively. Motor performance was measured 
with the Movement Assessment Battery for Children (movement-ABC). Age at testing: 6.1-
12.9 years. Mean time since completing treatment: 3.3 years. Results were compared 
to 155 healthy controls.
Results
Muscle strength of the survivors was reduced in ankle dorsiflexors on both sides (p< 
0.001), wrist dorsiflexors on the non-dominant side (p< 0.001) and pinch grip on the 
non-dominant (p=0.001) and dominant side (p=0.01). Passive ankle dorsiflexion of the 
survivors was significantly less on both sides (p<0.01). Movement-ABC percentile score 
was affected by pinch grip strength on the non-dominant (p<0.004), and dominant side 
(p=0.024) but not by strength of other muscle groups or by passive ankle dorsiflexion.
Conclusion
Peripheral muscle strength and ankle dorsiflexion are reduced in the long term in children 
treated for cancer with chemotherapy. However, neither decreased muscle strength nor 
reduced ankle dorsiflexion could completely explain reduced scores on the movement-
ABC.
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INTRODUCTION
During the last decades the survival of children diagnosed with cancer has increased 
substantially. One of the antineoplastic drugs contributing to the increased survival rate is 
vincristine, which is used among others in the treatment of acute lymphoblastic leukemia 
(ALL), Wilms’ tumor (WT), B-non-Hodgkin lymphoma (B-NHL) and malignant mesenchy-
mal tumors (MMT).
It is known from previous studies that children treated with vincristine for ALL show a de-
crease in motor performance, which may last a number of years following completion of 
chemotherapy 1-4. We recently showed that not only children with ALL but also with other 
malignancies, demonstrated impaired motor performance after chemotherapy containing 
vincristine 5. The underlying mechanism leading to this impaired motor performance is 
as yet unknown.
Reduced muscle strength may contribute to impaired motor performance and was report-
ed in three studies of patients treated for ALL 4,6,7. However these studies had limitations, 
because muscle strength was not measured with myometry but assessed with a motor per-
formance test 4, patients had received radiotherapy in addition to chemotherapy 4,6, or 
strength measurements were carried out whilst patients were still receiving chemotherapy 
treatment 7. Also, no data have been published on muscle strength in children who have 
completed chemotherapy treatment for childhood malignancies other than ALL.
Corticosteroids can cause myopathy 8 and may therefore have a negative effect on 
muscle strength. Corticosteroids are used in the treatment of both ALL and B-NHL.
Some ALL protocols contain vincristine /steroid pulses during maintenance therapy 
whereas other protocols do not, leading to large differences in cumulative vincristine 
and steroid doses. Whether muscle strength is affected by the use of these pulses during 
maintenance is unknown.
Reduced passive ankle dorsiflexion, which may also impair motor performance, was 
shown in 54 long-term survivors of ALL 9. Whether there was a relationship between loss 
of ankle dorsiflexion and impaired motor performance was not investigated.
The aims of the present study were to 1) investigate muscle strength and ankle dorsi-
flexion in children who had completed treatment for ALL, WT, B-NHL, and MMT, which 
included vincristine for all four types of malignancies and steroids for ALL and B-NHL, and 
2) to determine whether muscle strength or ankle dorsiflexion were related to an impaired 
motor performance score.
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METhODS
Patients
The study was conducted at the paediatric oncology departments of the Erasmus MC 
Sophia Children’s Hospital and the Emma Children’s Hospital AMC in the Netherlands. 
Approval of the Medical Ethical Committees in both hospitals was obtained. Children 
were included if they were aged 6-12 years at time of testing, had been diagnosed with 
ALL, WT, B-NHL or MMT and therapy had been completed at least one year prior to the 
study. They were excluded if they had a solid tumor whereby the location of the tumor 
itself could have contributed to motor problems, such as a tumor of the upper or lower 
limb. Cognitive impairment was also an exclusion criterion, as this may limit the child’s 
ability to understand and participate in muscle strength testing. The children took part 
in a larger study investigating motor problems in children treated for childhood cancer 
published by us earlier 5 and were selected on the basis of having received vincristine. 
Children attending a local school for primary education were invited to participate as 
controls. Informed consent was obtained from their parents.
Treatment
Children with ALL were treated according to the protocols of the Dutch Childhood Oncol-
ogy Group (DCOG): the Berlin-Frankfurt-Munster (BFM) based ALL-8 10 that does not con-
tain VCR/steroid pulses during maintenance and protocol ALL-9, which is almost identi-
cal to the previously used protocol ALL-6 and does contain VCR/steroid pulses during 
maintenance therapy 11. Protocols of the Societé Internationale d’Oncologie Pédiatrique 
(SIOP) were used to treat children with WT and MMT 12,13. Children with B-NHL were 
treated with DCOG-NHL-94 or LMB-96 protocol; these two protocols are very similar 14. 
Vincristine and steroid schedules are shown in Table I. Cumulative vincristine and steroid 
doses were obtained for each child by medical record extraction.
Table I Vincristine schedules
ALL-8 ALL-9 WT NHL MMT
cumulative vincristine dose in mg/m²
vincristine dose per administration in mg/m²
maximum vincristine dose per administration in mg
cumulative prednisone dose in mg/m²
cumulative dexamethasone dose in mg/m²
12-15
1.5
2.0-2.5
1933-1957
236
62-68
2.0
2.5
-
1244-1370
12-36
1.5
2.0
-
-
6-14
2.0
2.0
1417-1605
-
15-19.5
1.5
2.0
-
-
ALL-8 = acute lymphoblastic leukemia treated with DCOG protocol 8, ALL-9 = acute lymphoblastic leukemia 
treated with DCOG protocol 9, WT = Wilms’ tumor, NHL = non Hodgkin lymphoma, MMT = malignant 
mesenchymal tumor, mg/m² = milligrams per square meter body surface.
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Assessments
Height (in centimetres) and weight (in kilograms) of the children were measured. Muscle 
strength of dorsiflexors of feet and hands was assessed with a Citec 3001 hand held 
dynamometer (CIT Technics, Groningen, the Netherlands). The ‘break’ technique, de-
fined as ‘the examiner applying force to a child’s limb until the child’s capacity to hold 
is exceeded and the limb gives way’ was used to measure dorsiflexors of ankle and 
wrist (Figure 1)15. To measure grip strength children were asked to grip the hand held 
dynamometer, with a flexed elbow. Strength was measured in the positions described by 
Van der Ploeg 16. Measurements were carried out bilaterally and repeated three times 
each, as recommended by Horvat 17.
 
Figur  4/1  Measur m nt f muscl  strength  
 
 
Figure 1 Measuring strength of the wrist dorsiflexors, as an example of measuring muscle strength with a 
hand held dynamometer.
To assess joint mobility of the ankle, passive dorsiflexion was measured in supine position 
with the knee extended (Figure 2). A range of motion past the neutral position had a 
positive notation and less than neutral was negative.
The same physiotherapist - not blinded to whether a child was a survivor or a control - 
carried out all measurements.
Assessment of motor performance
Motor performance of the survivors was assessed with the Dutch version of the Movement 
Assessment Battery for Children (movement-ABC) 18,19 and was published earlier 5,18,19. 
The movement-ABC consists of a series of eight standardized tasks, which vary with age, 
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divided in three subsections: hand function, ball skills and balance skills. The total score 
of the movement-ABC is transformed by age-related norms into a percentile score. In 
addition the child’s performance on each of the subsections can be expressed as either 
below or above the 15th percentile. Validity of the movement-ABC to test motor ability in 
children has been shown before 20.
Statistical analysis
The SPSS statistical package (version 10.1) was used to analyse the data. Linear re-
gression analysis was used to determine whether muscle strength and passive ankle 
dorsiflexion differed between survivors and controls, taking into account age, gender, 
height and weight. In the survivors group the effect of cumulative vincristine, prednisone 
and dexamethasone dose on muscle strength was examined, controlling for the same 
variables as before and also for elapsed time since diagnosis.
Student’s t-test was used to determine differences in percentile score on the movement-
ABC of survivors with and without impaired ankle dorsiflexion.
 
Figure 4/2  Measurement of passive ankle dorsiflexion  
 
 
Figure 2 Measurement of passive ankle dorsiflexion in supine position, with the knee extended.
A goniometer is placed in line with the fibula and the lateral border of the foot. The axis of rotation is on 
the lateral malleolus.
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RESULTS
Patients
One hundred and sixteen children were eligible to participate in the study. The parents 
of 13 children did not respond to the request to participate. One child was excluded 
because he was diagnosed with Gilles de la Tourette syndrome. A total number of 102 
survivors entered the study. The results of ten children could not be used because they did 
not cooperate sufficiently. The remaining 92 children, 60 boys and 32 girls, had a mean 
age at follow-up time of 8.9 years (range 6.1-12.9) and mean time since completion 
of treatment was 3.3 years (range 1.0-7.5). Three children treated for MMT received 
radiotherapy, two to the facial area and one retroperitoneally. Five children who had 
been treated for WT received radiotherapy to the abdominal area and one child to the 
lungs. The control group consisted of 155 children, 77 boys and 78 girls, mean age 
9.5 years (range 6.5 to 12.9). Characteristics of the survivor and control groups are 
shown in Table II.
Table II Characteristics of survivors and controls
ALL-8
(n=14)
ALL-9
(n=30)
WT
(n=28)
B-NHL
(n=10)
MMT
(n=10)
survivors
(n=92)
controls
(n=155)
boys:girls 8 : 6 17:13 16:12 10 : 0 9 : 1 60 : 32 77 : 78
mean age at testing in 
years ± sd
9.6 ± 1.5 8.6 ± 2.1 8.9 ± 1.8 8.9 ± 1.6 8.9 ± 1.7 8.9 ± 1.8 9.5 ± 1.9
mean age at diagnosis in 
years ± sd
3.1 ± 1.0 4.3 ± 2.2 3.9 ± 2.2 5.7 ± 1.6 5.1 ± 1.7 4.3 ± 2.0 -
mean time since stop 
chemotherapy in years 
± sd
4.6 ± 1.5 2.0 ± 0.6 4.2 ± 1.7 2.9 ± 1.2 3.3 ± 0.9 3.3 ± 1.6 -
ALL-8 = acute lymphoblastic leukemia treated with DCOG protocol 8, ALL-9 = acute lymphoblastic leukemia 
treated with DCOG protocol 9, WT = Wilms’ tumor, NHL = non Hodgkin lymphoma, MMT = malignant 
mesenchymal tumor, sd = standard deviation.
Muscle strength
Muscle strength was evaluated in 92 survivors; the mean value of three repeated mea-
surements was used. Linear regression (controlling for gender, age, weight and height) 
showed that muscle strength of the survivors was reduced in the dorsiflexors of the ankle 
on both sides (p< 0.001), dorsiflexors of the wrist on the non-dominant side (p< 0.001), 
and pinch grip on both sides (non dominant p=0.001, dominant p=0.013) compared 
to the controls. Surprisingly, hand grip on the dominant side was significantly stronger in 
the survivor group (p = 0.025).
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Analysing the data using peak instead of mean strength values caused the difference in 
hand grip strength to lose its significance (Table III). Mean and peak strength values for 
survivors and controls, grouped by age, are presented in Table IV.
Passive ankle dorsiflexion
Passive dorsiflexion of the ankle was measured in 64 survivors. We first examined whether 
dorsiflexion was affected by age, gender, height or weight by analysing the data of the 
controls and found that only weight had a significant effect (p=0.007). When controlling 
for weight, passive ankle dorsiflexion of the survivors was significantly less on the non-
dominant side (mean difference 1.6 º, s.e. 0.9, p = 0.009) and on the dominant side 
(mean difference 1.8 º, s.e. 0.6, p=0.004) compared to the controls. Ankle dorsiflexion 
values for survivors and controls, grouped by age, are presented in Table V.
During a normal gait cycle active ankle dorsiflexion reaches 5º or more 21. Passive 
dorsiflexion mobility needs to be at least 5º in order for the ankle to move normally. We 
therefore defined ≤ 5° of passive dorsiflexion as ‘impaired’. With this criterion applied, 
32% of the survivors would be impaired compared to 14% of the controls. There were no 
significant differences in percentile score on the movement-ABC between survivors with 
normal or impaired ankle dorsiflexion (p=0.52).
Cumulative vincristine and steroid dose
In the survivor group regression analysis, controlling for age, gender, weight, height and 
elapsed time since diagnosis, showed that neither cumulative vincristine, prednisone or 
dexamethasone dose decreased muscle strength. We found a positive effect of predni-
Table III Differences in mean strength and peak strength values between survivors and controls
Mean strength Peak strength
ankle dorsiflexors
non-dominant side
dominant side
-13.0 (2.2)
-12.2 (2.1)
p<0.001*
p<0.001*
- 14.4 (2.5)
- 13.4 (2.4)
p<0.001*
p<0.001*
wrist dorsiflexors
non-dominant side
dominant side
- 4.2 (0.9)
- 0.5 (1.2)
p<0.001*
p=0.675
- 3.5 (1.1)
- 0.04 (1.4)
p=0.002*
p=0.979
pinch grip
non-dominant side
dominant side
- 4.2 (1.3)
- 3.4 (1.3)
p=0.001*
p=0.013*
- 4.5 (1.4)
- 3.7 (1.4)
p=0.001*
p=0.011*
hand grip
non-dominant side
dominant side
2.1 (1.4)
3.1 (1.4)
p=0.121
p=0.025*
1.9 (1.4)
2.6 (1.5)
p=0.199
p=0.08
Mean strength (standard error) and peak strength (standard error) in Newtons; negative values indicate
that survivors are weaker than controls; * denotes statistical significance.
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Table IV Muscle strength values of survivors (s) and controls (c)
Muscle group Gender Age
6 7 8 9 10 11 12
ankle 
dorsiflexors
non-dominant 
side
boys (s) 40.6 (6.7) 50.0 (13.0) 45.5 (7.5) 50.1 (11.8) 52.9 (8.1) 67.9 (21.5) 63.2 (11.7)
boys (c) 68.6 (11.8) 54.8 (12.0) 56.8 (10.1) 61.5 (9.2) 85.8 (30.7) 73.6 (24.1) 76.8 (12.0)
girls (s) 41.6 (2.8) 40.7 (5.8) 53.7 (5.5) 50.7 (12.0) 47.9 (8.5) 60.4 (16.2) 47.7 (1.0)
girls (c) 51.8 (16.4) 58.9 (17.0) 59.5 (11.4) 67.7 (22.9) 65.5 (16.6) 77.5 (20.1) 74.3 (16.0)
ankle 
dorsiflexors
dominant side
boys (s) 41.8 (7.3) 51.6 (12.2) 46.0 (7.0) 52.2 (14.3) 53.1 (5.4) 67.6 (17.5) 60.2 (20.0)
boys (c) 69.9 (11.7 57.5 (8.8) 60.4 (10.8) 61.6 (10.8) 80.9 (26.2) 66.0 (12.1) 79.3 (15.0)
girls (s) 38.8 (7.2) 44.3 (8.1) 51.8 (11.2) 45.9 (10.3) 48.8 (13.5) 50.7 (11.9) 56.3 (10.4)
girls (c) 48.0 (12.3) 55.3 (16.1) 57.1 (13.0) 72.4 (22.9) 63.6 (14.9) 78.0 (21.9) 78.7 (23.7)
wrist 
dorsiflexors
non-dominant 
side
boys (s) 32.8 (6.7) 37.2 (7.6) 32.2 (6.2) 41.0 (9.8) 38.4 (7.9) 49.1 (8.1) 46.2 (14.1)
boys (c) 38.1 (4.2) 38.6 (7.3) 38.0 (5.9) 40.7 (5.2) 46.1 (4.5) 47.3 (4.1) 50.5 (8.9)
girls (s) 27.7 (3.8) 30.2 (7.1) 35.7 (11.4) 28.7 (1.7) 36.4 (13.5) 42.2 (5.0) 39.0 (9.0)
girls (c) 34.6 (5.9) 34.7 (3.1) 37.0 (4.7) 39.9 (3.8) 44.0 (5.3) 47.6 (3.7) 53.1 (9.4)
wrist 
dorsiflexors
dominant side
boys (s) 33.7 (7.6) 36.4 (9.4) 37.8 (9.9) 44.0 (9.8) 47.5 (10.1) 56.5 (18.3) 54.2 (22.0)
boys (c) 38.5 (4.9) 36.3 (4.6) 41.9 (10.4) 41.7 (4.7) 49.7 (3.8) 48.4 (8.9) 49.8 (8.6)
girls (s) 28.1 (3.0) 34.4 (6.4) 37.5 (13.4) 34.9 (12.1) 38.1 (11.4) 45.6 (11.0) 43.2 (7.9)
girls (c) 33.0 (4.6) 35.1 (6.1) 36.4 (9.0) 43.4 (5.8) 48.6 (6.6) 45.5 (6.3) 50.9 10.0)
3-point grip
non-dominant 
side
boys (s) 28.0 (5.7) 40.0 (10.5) 39.0 (6.9) 50.8 (4.7) 51.8 (7.7) 55.5 (10.8) 56.0 (14.7)
boys (c) 36.0 (6.82) 46.6 (11.4) 45.3 (8.1) 48.5 (6.3) 55.8 (9.7) 61.0 (8.7) 72.0 (12.0)
girls (s) 28.9 (6.2) 35.6 (9.9) 37.8 (11.7) 38.6 (7.7) 48.1 (11.5) 54.8 (10.9) 58.2 (7.8)
girls (c) 33.3 (5.8) 36.0 (8.8) 41.8 (11.2) 46.2 (8.4) 50.5 (18.1) 64.4 (6.5) 62.5 10.1)
3-point grip
dominant side
boys (s) 29.8 (6.4) 42.2 (9.6) 44.9 (8.0) 53.5 (8.6) 57.5 (12.5) 63.3 (11.2) 61.5 (7.7)
boys (c) 32.4 (7.0) 48.7 (11.5) 49.5 (8.3) 54.3 (9.7) 61.5 (9.3) 67.2 (9.7) 78.5 (10.9)
girls (s) 27.1 (6.8) 38.0 (8.2) 43.7 (10.8) 43.4 (12.9) 51.9 (5.7) 59.0 (10.6) 59.2 (3.1)
girls (c) 32.6 (5.4) 36.2 (9.4) 46.5 (10.5) 51.8 (11.3) 55.3 (14.4) 70.6 (9.9) 66.0 (14.0)
hand grip
non-dominant 
side
boys (s) 29.1 (3.7) 42.4 (9.9) 42.6 (12.7) 56.4 (8.8) 57.3 (11.2) 59.5 (15.0) 66.2 (11.9)
boys (c) 32.3 (6.5) 39.4 (7.8) 43.0 (11.0) 50.6 (8.9) 56.2 (5.6) 57.1 (7.8) 73.7 (11.6)
girls (s) 25.7 (5.2) 39.0 (6.7) 43.7 (7.0) 42.0 (8.4) 42.0 (8.0) 64.3 (15.0) 53.0 (1.9)
girls (c) 28.1 (4.0) 34.3 (7.4) 37.1 (9.4) 43.5 (10.8) 47.2 (14.2) 68.2 (14.0) 60.0 (9.1)
hand grip
dominant side
boys (s) 32.9 (8.2) 44.8 (11.5) 48.5 (13.0) 57.7 (12.8) 64.4 (10.7) 68.9 (11.6) 74.6 (15.9)
boys (c) 33.0 (4.8) 43.2 (7.5) 46.8 (14.3) 56.0 (11.8) 63.6 (9.1) 63.7 (10.1) 82.5 (9.0)
girls (s) 24.0 (3.2) 39.6 (3.5) 41.5 (9.3) 44.1 (11.5) 47.1 (4.6) 68.3 (17.0) 64.3 (1.0)
girls (c) 29.9 (4.9) 34.3 (8.0) 40.1 (10.9) 44.6 (11.6) 49.4 (13.9) 70.8 (12.8) 65.8 (12.1)
Mean values (sd) in Newtons.
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sone on strength of dorsiflexors of the ankle on both the non-dominant and the dominant 
side (factor 0.003, p=0.03).
Analysing the data, using peak instead of mean strength values did not change the 
results. Analysing the results omitting four cases where the VCR dose was topped also 
made no difference.
Motor performance
In the survivors group the relationships between muscle strength and movement-ABC 
scores were also examined. Regression analysis, controlling for age, gender, weight, 
height and elapsed time since diagnosis, showed that decrease in strength of wrist 
dorsiflexors on the dominant side had a significant adverse effect on hand function score 
(factor 0.06, p=0.02) and on total score (factor -0.147, p=0.03) but not on percen-
tile score (p=0.61). Decrease in pinch grip strength on both sides adversely affected 
ball skill score (non-dominant side factor -0.06, p=0.03; dominant side factor -0.07, 
p=0.01), total score (non-dominant side factor -0.17, p=0.04; dominant side factor 
-1.9, p=0.03) and percentile score (non-dominant side factor 1.1, p=0.004; dominant 
side factor 0.8, p=0.02). Analysing the data using peak strength values did not alter 
the results.
DISCUSSION
This study shows decreased strength of dorsiflexors of ankles and wrists and of pinch grip 
in children treated with chemotherapy including vincristine for ALL, WT, B-NHL and MMT, 
Table V Ankle dorsiflexion mobility of survivors (s) and controls (c)
Gender Age
6 7 8 9 10 11 12
ankle 
dorsiflexion
non-dominant 
side
boys (s) 8.3 (5.8) 9.5 (5.1) 7.4 (6.2) 5.0 (2.5) 8.0 (2.6) 4.5 (3.7) 5.3 (5.5)
boys (c) 10.2 (5.7) 9.5 (5.5) 10.9 (5.1) 9.1 (3.6) 9.7 (4.0) 9.5 (2.5) 12.0 (5.8)
girls (s) 6.4 (4.2) 7.6 (3.4) 9.3 (1.9) 6.7 (2.9) 7.2 (7.2) 6.8 (3.9) 5.5 (4.2)
girls (c) 10.0 (1.6) 9.1 (1.8) 11.8 (5.1) 10.0 (3.5) 8.8 (3.3) 11.9 (4.3) 12.8 (4.7)
ankle 
dorsiflexion
dominant side
boys (s) 8.3 (5.8) 9.5 (5.1) 6.9 (4.7) 5.7 (3.1) 8.7 (2.7) 5.8 (3.4) 7.5 (3.5)
boys (c) 9.3 (5.1) 8.9 (4.9) 10.8 (3.0) 11.6 (4.2) 10.5 (3.8) 9.1 (2.6) 11.3 (2.2)
girls (s) 6.8 (3.4) 8.0 (2.7) 9.3 (1.9) 6.7 (2.9) 6.2 (5.0) 6.3 (4.3) 7.5 (3.5)
girls (c) 9.6 (1.6) 9.4 (1.8) 10.6 (2.7) 9.8 (4.3) 9.3 (4.6) 11.5 (4.7) 10.5 (0.8)
Mean values (sd) in degrees.
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tested at least one year after completion of treatment. Vincristine is known to decrease 
peripheral muscle strength during treatment 22,23. In the present study, several years after 
completion of treatment, we did not find that the decrease depended on cumulative 
vincristine dose.
Another cause for the reduction in muscle strength could have been treatment with corti-
costeroids. Steroid-induced myopathy, resulting in muscle weakness predominantly in the 
proximal muscles of upper and lower limbs has been described 22.
However, we did not study proximal muscle groups, such as flexors and extensors of 
hip and knee, because values of more than 350 N were found in those muscle groups 
in healthy children 24 and values over 350 N are less reliable than values below 350 
N when measured with a hand held dynamometer 25. Also, reliability is reduced if the 
measured muscles are strong relative to the strength of the tester 26. From our data we 
can conclude that steroids had no adverse effect on the peripheral muscle groups we 
tested. The only significant effect was a positive effect of prednisone on ankle dorsiflexor 
strength, which we consider a spurious finding. Measuring strength of the ankle plantar 
flexors, which have an important function in every day activities such as walking, running 
and jumping would be of interest to us. Normal strength of the ankle plantar flexors is 
considerable, as is demonstrated by the fact that healthy children are able to stand on 
tiptoe of only one foot. In addition leverage on the foot is very short. This makes it difficult 
to obtain reliable data.
Muscle strength values for healthy Dutch children have been published before 24. How-
ever, no inter-observer or intra-observer reliability data were reported. Also the numbers 
in the various age groups were small. We therefore decided we could not use them as 
normative values and measured our own controls.
Nine children were treated with radiation, but this was applied to areas which would 
have no effect on muscle strength or ankle dorsiflexion mobility.
Reduction of passive ankle dorsiflexion following treatment for ALL has been shown 4,9,27. 
Our study also demonstrates reduced ankle dorsiflexion mobility in children who have 
been treated for other types of childhood cancers. The loss of mobility is likely to be 
caused by weakness of the ankle dorsiflexors, which occurs during treatment 7 and 
continues after treatment (present study), resulting in shortening of the gastrocnemius 
muscle.
In the present study impaired ankle dorsiflexion mobility did not affect percentile score on 
the movement-ABC test. Whether the loss of passive ankle dorsiflexion has an adverse 
affect on activities of daily life cannot be deducted from these results, as the movement-
ABC does not measure activities such as walking or running, 21.
Apart from pinch grip strength on both sides, we could not show a relationship be-
tween impaired muscle strength in any of the other muscle groups and the reduced 
movement-ABC scores we reported earlier 5. The considerable decrease in strength of 
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the ankle dorsiflexors was not associated with a reduction in motor performance score. 
The movement-ABC is designed to assess the every day motor competence of children 18, 
but gives no information about the actual cause of a potential impairment in performance 
28, which may explain the lack of relationship.
Our results suggest that the impaired scores on the movement-ABC cannot be completely 
explained by the reduction in muscle strength we demonstrated in the ankle and wrist dor-
siflexors and in pinch grip strength. They also show that muscle strength in the survivors 
group is not impaired to such an extent that it affects every day activities as measured 
by the movement-ABC. The clinical relevance of the reduction in strength is difficult to 
determine and the impact may differ depending on the children’s motor competence prior 
to the onset of their illness. Those children who used to be ‘good performers’ may still 
perform relatively well, even with reduced muscle strength, whereas children who were 
previously less skilled no longer manage to score within the norm on the movement-ABC. 
Because movement-ABC scores were not measured prior to starting chemotherapy, a 
possible reduction in motor competence in individual children could not be determined.
In conclusion, this study shows reduced strength of ankle and wrist dorsiflexors and pinch 
grip and reduced ankle dorsiflexion mobility in the long-term in children treated for can-
cer with chemotherapy. However, neither decreased muscle strength nor reduced ankle 
dorsiflexion could completely explain he reduction in score on the movement-ABC.
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ABSTRACT
Background
Perceived athletic competence is an important factor in self-esteem of children. Motor 
problems have been described in children who were treated for cancer with protocols 
including vincristine. In the present study we investigated whether perceived motor com-
petence of children was decreased following treatment for cancer and the relationship 
with actual motor performance.
Procedure
Fifty-three children (age 8-12 years), who had completed chemotherapy including vincris-
tine for childhood cancer at least one year earlier, were asked to complete the m-CBSK 
questionnaire for perceived motor competence. Their actual motor performance scores 
were measured with the Movement Assessment Battery for Children (movement-ABC).
Results
The perceived motor competence score of the ex-patients did not significantly differ from 
the reference normal values (p=0.95). A moderate but significant correlation between 
perceived motor competence and actual motor competence was found (rs = 0.375, 
p=0.006). In 77% of the cases the movement-ABC score was lower than the perceived 
competence score.
Conclusion
Children who had completed treatment with chemotherapy for cancer did not show 
an impaired perceived motor competence, but they had a tendency to overrate their 
performance.
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INTRODUCTION
In children, self-esteem is thought to depend on a number of factors, one of which is 
athletic competence 1. A child’s perception of ‘ being like their peers’, ‘fitting in with the 
group’ and ‘not being any different’ contributes to positive self-perception, which in its 
turn is an important factor for a child’s ability to adjust to life situations 2. Motor problems 
have been described in 30% to 100% of children with acute lymphoblastic leukemia 
(ALL), two to seven years after completion of treatment 3-6. A recent study showed that 
children with other malignancies, who were treated with regimens which contained 
vincristine, had an impaired motor performance 7. It is not known how children who 
have completed chemotherapy perceive their motor competence and whether this has a 
negative influence on their self-esteem.
The studies that analysed quality of life, body image and self-esteem after completion of 
treatment for childhood cancer have not answered this question. The subjects of some 
studies were adolescents and adults 8-12. In one study parents were questioned, but not 
their children 13. One study investigating opinions of children was carried out during 
treatment 14. In another study that took place after completion of treatment, no difference 
in self-perception was found between 56 ex-patients aged 5-12 and a control group 15. 
In this study the Self-Perception Profile for Children (SPPC) was used, which has a global 
self-worth domain and five various sub-domains, including ‘athletic competence’ 1. How-
ever, as each domain is evaluated by only six questions, the athletic competence domain 
provides a limited view of the children’s perception of their motor performance.
Vincristine, which is used in treatment protocols for various childhood malignancies, 
causes polyneuropathy which may lead to a decrease in muscle strength in upper and 
lower extremities 16. We recently showed that children with malignancies demonstrated 
impaired motor performance after vincristine containing chemotherapy 7.The aim of the 
present study was to evaluate the perceived competence of children treated for cancer 
with chemotherapy including vincristine regarding motor skills. In addition, we analysed 
whether their perceived motor competence is related to actual motor performance.
METhODS
Patients
The study was conducted in the pediatric oncology departments of the Erasmus MC 
Sophia Children’s Hospital, Rotterdam, and the Emma Children’s Hospital, Amsterdam, 
in the Netherlands. Approval from the Medical Ethics Committees of both hospitals was 
obtained. Informed consent was obtained from the parents of all participating children.
Eligibility criteria were as follows:
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- being in complete remission after treatment for acute lymphoblastic leukemia, Wilms’ 
tumor (WT), B-non Hodgkin lymphoma (B-NHL) or malignant mesenchymal tumor 
(MMT) i.e. soft tissue sarcomas.
- earlier chemotherapy contained vincristine
- at least one year after completion of therapy at time of testing
- age 8-12 years at time of testing (because the test used to measure self-perception 
is validated for this age category)
- attending regular primary school education
Children were excluded if they had a solid tumor whereby the location of the tumor itself 
could have contributed to motor problems, such as a tumor of the upper or lower limb or 
central nervous system.
Data on age at testing, age at diagnosis, cumulative vincristine dose, duration of chemo-
therapy and time since completion of chemotherapy were collected. The children took 
part in a larger study that investigated motor problems in children treated for childhood 
cancer 7.
Treatment
Children with ALL were treated according to the protocols of the Dutch Childhood Oncol-
ogy Group: the Berlin-Frankfurt-Munster based ALL-8 17 and protocol ALL-9, that is almost 
identical to the previously used protocol ALL-6 18. Children with WT and MMT were 
treated with protocols of the Societé Internationale d’Oncologie Pédiatrique (SIOP) 19-21 
and children with B-NHL received DCOG-NHL-94 or LMB-96 protocol; the latter two 
protocols are very similar 22. Maximum vincristine dose per administration varies by 
protocol: 2.0 –2.5 mg; cumulative vincristine doses in the above mentioned treatment 
protocols also vary as shown in Table I. Cumulative vincristine doses were obtained for 
each child from the medical records.
Table I Vincristine schedules
ALL-8 ALL-9 WT NHL MMT
cumulative vincristine dose in mg/m²
vincristine dose per administration in mg/m²
maximum vincristine dose per administration in mg
cumulative prednisone dose in mg/m²
cumulative dexamethasone dose in mg/m²
12-15
1.5
2.0-2.5
1933-1957
236
62-68
2.0
2.5
-
1244-1370
12-36
1.5
2.0
-
-
6-14
2.0
2.0
1417-1605
-
15-19.5
1.5
2.0
-
-
ALL-8 = acute lymphoblastic leukemia treated with DCOG protocol 8, ALL-9 = acute lymphoblastic leukemia 
treated with DCOG protocol 9, WT = Wilms’ tumor, NHL = non Hodgkin lymphoma, MMT = malignant 
mesenchymal tumor, mg/m² = milligrams per square meter body surface.
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Assessment of motor performance
Motor performance was measured using the Dutch version of the Movement Assessment 
Battery for Children (movement-ABC) 23,24. The movement-ABC consists of a series of 
eight standardized tasks divided in three subsections: hand function, ball skills and bal-
ance skills. The tasks vary with age and are designed to resemble every day activities 
of children. The total score of the movement-ABC is transformed by age-related norms 
into a percentile score. A score below the 5th percentile is indicative of a motor problem, 
between 5th and 15th percentile is borderline and higher than the 15th percentile is 
normal. The child’s performance on each of the subsections is also expressed as either 
below or above the 15th percentile. The validity of the movement-ABC to test motor ability 
in children has been demonstrated 25.
All measurements were carried out by the same pediatric physiotherapist.
Assessment of perceived motor competence
Children were asked to complete the motor supplement of the ‘Competentie BelevingsS-
chaal voor Kinderen’ (m-CBSK) 26, which is an extension of the ‘athletic competence’ 
domain of the SPPC 1. This test was developed specifically for Dutch children aged 8-12 
years. Internal consistency and test-retest reliability of the m-CBSK have been shown to 
be satisfactory (Cronbach’s alpha 0.77, rp = 0.83) 
26.
The questionnaire consists of 17 questions covering a range of motor skills needed for 
outdoor activities, physical education classes, and sports such as throwing and catch-
ing a ball, running and jumping. As in the SPPC, children are asked to rate their motor 
competence in relation to the motor performance of their peers. The construction of the 
questions is two-tiered. Children are first asked to choose which child is most like him or 
her: a child who performs well or a child who performs less well. They are then asked 
whether ‘this is only sort of true’ or ‘really true’. An example of such a question is:
really
true
for me
sort of
true
for me
some children
are very good
at jumping
BUT other children
are not so good
at jumping
sort of
true
for me
really
true
for me
   
The procedure was first explained to the child and his parents and then practiced with 
the child. The questionnaire was then completed at home. If necessary, parents were 
allowed to help with reading of the questions, providing they did not supply their child 
with an answer. The two-tiered construction discourages responses which are led by 
social desirability 26,27. Total scores (ranging from 12-48 points) are transformed into 
decile scores, which differ for boys and girls.
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On completing the questionnaire the child is asked to rate the importance of the motor 
competence domain in comparison to five other domains such as ‘doing well at school’, 
‘looking nice’ etc. Each domain yields a score from 1- 4; a domain with a score ≥ 3 is 
considered important to the child.
Statistics
The SPSS statistical package (version 10.1) was used to analyse the data. A Wilcoxon 
signed rank test was used to analyze differences in perceived motor competence with 
the normal population. Group differences were analysed with the Mann Whitney and 
Kruskal-Wallis test. The Spearman correlation coefficient was calculated to investigate 
relationships between perceived motor competence and age at time of testing, age at 
diagnosis, duration of treatment, time since completion of treatment and motor perfor-
mance on the movement-ABC.
RESULTS
Patients
The m-CBSK questionnaire, consisting of ‘perceived motor competence’ and ‘importance 
of motor domain’ was handed out to 61 children from our previous cohort, aged 8-12. 
Six children did not return the questionnaire; their patient characteristics did not differ 
from the rest of the group. Fifty-five children completed and returned the perceived motor 
competence questionnaire; two of those could not be used because more than one reply 
was given to a question. One of the children did not complete the ‘importance of motor 
domain’ part. Of the 53 remaining participants 34 were boys (64%) and 19 were girls 
(36%). They had been treated for various conditions: 26 for ALL (12 with ALL-8 and 
14 with ALL-9 protocol), 4 for MMT, 15 for WT and 8 for NHL. One of the children 
treated for MMT received retroperitoneal radiation. Of the children treated for WT three 
received radiation to the abdominal area and one to the lungs. Mean age at testing was 
10.2 years (± 1.3). The children’s age at diagnosis ranged from 1.7-8.8 years (mean 
5.2 ± 1.9), duration of chemotherapy ranged from 0.2-2.3 years (mean 1.3 ± 0.8), 
time since completion of treatment from 1.4-7.1 years (mean 3.6 ± 1.7) and cumulative 
vincristine dose from 5.0 – 68.0 mg/m² (mean 29.6 ± 24.0) (Table II).
Perceived motor competence
Total scores of perceived motor competence were transformed into decile scores. There 
was no significant difference in perceived motor competence between the study group 
and the reference values (p=0.95); median decile score was 6.0 for the ex-patients.
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In the study group 24 children (45%) considered the motor domain of importance. There 
was no significant difference in perceived motor competence between children who 
considered the motor domain important and those who did not (p=0.34), with median 
decile scores of 6.5 and 5.5 respectively (Figure 1).
There was no difference in perceived motor competence between boys and girls (p = 
0.56). Perceived motor competence was not affected by age at time of testing (rs = 
-0.05, p = 0.71), age at diagnosis (rs = 0.08, p = 0.59), duration of treatment (rs = 
Table II Patient characteristics
ALL-8
(n=12)
ALL-9
(n=14)
WT
(n=15)
NHL
(n=8)
MMT
(n=4)
total group
(n=53)
boys : girls 8 : 4 8 : 6 8 : 7 7 : 1 3 : 1 34 : 19
mean age at testing in years 
± sd
10.2 ± 1.2 10.3 ± 1.5 10.3 ± 1.5 9.7 ± 0.9 10.3 ± 1.8 10.2 ± 1.3
mean age at diagnosis in 
years ± sd
3.3 ± 1.3 5.8 ± 1.7 5.5 ± 1.6 6.3 ± 1.6 5.5 ± 1.9 5.2 ± 1.9
chemotherapy duration in 
years ± sd
2.0 ± 0.02 2.1 ± 0.06 0.7 ± 0.4 0.4 ± 0.3 0.5 ± 0.3 1.3 ± 0.8
mean time since stop 
chemotherapy in years ± sd
5.0 ± 1.2 2.1 ± 0.5 4.0 ± 1.9 3.2 ± 1.2 4.4 ± 1.3 3.6 ± 1.7
mean cumulative vincristine 
dose in mg/m² ± sd
12.0 ± 0.0 66.0 ± 3.7 24.5 ± 10.5 8.3 ± 1.9 13.9 ± 2.8 29.6 ± 24.0
ALL-8 = acute lymphoblastic leukemia treated with DCOG protocol 8, ALL-9 = acute lymphoblastic leukemia 
treated with DCOG protocol 9, WT = Wilms’ tumor, NHL = non Hodgkin lymphoma, MMT = malignant 
mesenchymal tumor, sd = standard deviation.
 
Figure 5/1  Importance of motor domain 
 
 
important unimportant
0
1
2
3
4
5
6
7
8
9
10
pe
rc
ei
ve
d 
co
m
pe
te
nc
e 
(d
ec
ile
s)
Figure 1 Perceived motor competence of children who considered the motor domain important and those 
who did not. The horizontal bars depict the median values.
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-0.22, p = 0.12), time since completion of chemotherapy (rs = 0.01, p = 0.96), time 
since completion of vincristine administration (rs = 0.08, p=0.59), cumulative vincristine 
dose ( rs = -0.12, p=0.41) or type of malignancy (p=0.26).
Actual motor competence
Percentile scores of the ex-patients on the movement-ABC test were significantly lower 
than reference values (p < 0.001). The median percentile score of the ex-patients was 
25.0. Scores below < 15th percentile were found in 32% of the children.
There was a weak but significant correlation between movement-ABC score and per-
ceived motor competence (rs = 0.38, p = 0.01). In 77% of the cases (n=41) the score 
on the movement-ABC was lower than the perceived competence score (Figure 2). There 
was no significant difference in movement-ABC score between children who considered 
the motor domain important and those who did not (p = 0.69).
Actual motor competence did not differ between boys and girls (p = 0.59). Actual motor 
competence was affected by age at time of testing (rs = -0.33, p = 0.02), but not by 
age at diagnosis (rs = -0.02, p = 0.91), duration of treatment (rs = -0.17, p = 0.24, 
time since completion of chemotherapy (rs = -0.14, p = 0.33), time since completion of 
vincristine administration (rs = -0.15, p=0.29), cumulative vincristine dose ( rs =-0.14, 
p=0.34) or type of malignancy (p=0.54). Motor competence of children who had 
received corticosteroids did not differ from those who had not (p=0.62).
 
Figure 5/2  Perceived motor competence and actual motor performance 
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Figure 2 Perceived motor competence and actual motor performance. This figure represents all 53 cases; 
some children had identical scores. Scores below the dotted line (x = y) indicate overrating of motor per-
formance.
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DISCUSSION
Children with physical differences are suggested to be at risk for negative social percep-
tions and behaviours and loss of self-esteem 28,29 and during chemotherapy children 
show dissatisfaction with their athletic performance 30. As impaired motor performance 
is one of the late effects of chemotherapy 7, we hypothesised that that children who 
had been treated with chemotherapy would have low perceived motor competence. 
However our results showed that their perceived motor competence did not differ from 
the reference values.
We found a weak but significant correlation between perceived competence and actual 
motor performance. This indicates that children who performed better on the motor test 
did rate themselves more highly than those with lower scores. However, in 77% of the 
cases the actual movement-ABC score was lower than the perceived competence score 
indicating that the majority of children were ‘overrating’ their performance. An explana-
tion for this tendency to ‘overrate’ may be to try to avoid being pitied, or having their 
parents worry about them. Also they may wish to be ‘normal’, something that has been 
observed in a study of adolescent cancer survivors 31. Ex-patients may also overrate their 
motor performance because they have known an earlier treatment period during which 
they felt less able, which changed their frame of reference.
The results on the perceived motor competence test and the actual motor performance test 
could have been a mere reflection of the treatment with vincristine. A higher cumulative 
vincristine dose might lead to impaired motor performance, which could subsequently 
result in a lower perception score. Our results show that neither was the case. Other 
variables related to vincristine treatment such as ‘duration of treatment’ and ‘time since 
completion of treatment’ also had no effect on perceived motor competence or actual 
motor performance.
Five children received radiation, but this was applied to areas that would have no effect 
on motor performance.
The m-CBSK test does not contain items that ask children to specify who they consider 
to be their peers, which would affect the way they rate their own performance. It is un-
known whether children who have had cancer are different from the general population 
in choosing their peer group. Whether the relationship between perceived and actual 
motor competence of the children in the present study is different from the general popula-
tion is also unknown. There are no other studies where children have been examined 
with both the m-CBSK and the movement-ABC.
Interestingly, the percentage of children in this study who rated the motor domain as 
‘important’ (45%) seems noticeably lower than the 70% found in the general popula-
tion 26.
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The m-CBSK is validated for children aged 8-12 years. Whether our results hold true for 
younger or older children is therefore uncertain. Particularly older children may have a 
different view on body image and social quality of life.
A potential source of bias in this study is the fact that parents were allowed to assist their 
child in completing the survey, in case of reading difficulties. Although parents were 
instructed only to assist their child in case he or she did not know the meaning of a word, 
their assistance may still have altered the child’s response.
Although the children in this study may find motor competence of less importance then 
their peers and they have a tendency to overrate their competence, the results could still 
be considered positive, as the majority of children appeared to be satisfied with their 
motor performance.
In conclusion, the perceived motor competence of children who had completed treatment 
with chemotherapy for cancer did not differ from the general population. However, the 
ex-patients had a tendency to overrate their actual motor performance.
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ABSTRACT
Background
Impaired motor performance has been demonstrated in children treated with vincristine 
containing chemotherapy for cancer, but there was no relationship with the dose-schedule 
of vincristine. We analysed whether genetic variation of the drug metabolising gene 
CYP3A5, and VCR–toxicity related genes MDR-1 and MAPT is related to impaired motor 
performance in children with acute lymphoblastic leukemia (ALL).
Methods
In 34 children, aged 4-12, who had completed treatment for ALL for at least one year, 
motor performance was measured with the movement Assessment Battery for Children 
(m-ABC). DNA, extracted from mononuclear peripheral blood cells, was genotyped for 
CYP3A5*3/*3 and *1/*3, MDR-1 (C1236T, G2677T, C3435T) and MAPT poly-
morphisms.
Results
There was no significant difference in m-ABC percentile scores between cases with CY-
P3A5 *3/*3 and CYP3A5*1*3 genotypes. Percentile scores were also not significantly 
affected by MDR-1 C1236T, C3435T, or G2677T single nucleotide polymorphisms 
(SNP) nor was the difference between carriers of 3435C/2677G, 3435T/2677G 
and others significant. In addition, no significant difference was found between MAPT 
haplotype A and haplotype B.
Conclusion
Our data do not provide evidence that CYP3A5, MDR-1 or MAPT genetic polymor-
phisms are linked with impaired motor performance in children who had been treated 
with vincristine containing chemotherapy for ALL.
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INTRODUCTION
Survival of children treated for cancer has increased dramatically since the 1950’s 
amongst others by improvements in chemotherapy. However, chemotherapy can give 
rise to a number of side effects, which may remain present after completion of treatment. 
Impaired motor performance has been described in children treated for acute lympho-
blastic leukemia (ALL) with chemotherapy protocols containing vincristine (VCR) 1-4. A 
known complication of treatment with VCR is the development of polyneuropathy, which 
can result in loss of peripheral muscle power in upper and lower extremities 5. It has often 
been assumed that there is a positive relationship between cumulative VCR dose and 
the severity of motor problems 5-7. However, a recent study showed that impaired motor 
performance was not related to frequency, dose, or cumulative dose of VCR. Also, in 
children treated with identical protocols motor performance varied greatly 8. The cause of 
differences in susceptibility for disturbances in motor performance is yet unknown.
VCR belongs to the group of vinca-alkaloid drugs metabolised by the cytochrome P450 
system in the liver 9. Isoforms of this system expressed in humans are CYP3A4 and 
CYP3A5. Polymorphisms of CYP3A4 exist but are rare 10. In contrast, CYP3A5 polymor-
phisms are relatively common in the Caucasian population. Reports on the expression of 
CYP3A5 vary from 10% - 40%, which is caused by the A6986G genetic polymorphism 
(CYP3A5*3 variant allele) in the CYP3A5 gene 11,12. The estimated hepatic clearances 
of VCR were 5-fold higher for CYP3A5 high expressers compared to CYP3A5 non-
expressers 13. As VCR is known to cause polyneuropathy, which can subsequently give 
rise to motor problems, a link may exist between the presence of a CYP3A5 polymor-
phism and the level of motor performance of children treated with vincristine as part of 
their chemotherapy.
The multi drug resistance (MDR-1 or ABCB1) gene is also involved in the pharmacokinet-
ics of VCR. Upregulation of the MDR-1 gene encoding for P-glycoprotein (P-gp), an efflux 
pump, results in a decrease in intracellular concentration of VCR and an increase in 
biliary clearance 14,15. So far, at least 29 single nucleotide polymorphisms (SNPs) have 
been described of the MDR-1 gene. Two of these, C3435T and G2677A/T influence 
the pharmacokinetics of P-gp substrates 16-18. No association was observed between 
C3435T or G2677T and vincristine pharmacokinetics, but when haplotypes as de-
scribed by Johne 19 were assigned, haplotype 1/1 carriers (3435C/2677G) showed 
a longer elimination half-life for vincristine than non-carriers 20. Haplotype 1/2 carriers 
(3435T/2677G) may have a shorter elimination half-life. Another SNP, C1236T has 
been linked to C3435T and G277T/A, although no effect on pharmacokinetics has 
been described 21.
Thirdly, genetic variation in the microtubule-associated protein tau (MAPT) gene may 
influence VCR effects at the tissue level. MAPT promotes the assembly and stabilisation of 
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microtubules, which form a target for VCR. When VCR damages microtubules, apoptosis 
occurs. MAPT abnormalities have been linked to a number of neurodegenerative disor-
ders e.g. Parkinson’s disease, progressive supranuclear palsy, and Alzheimer’s disease 
22-24.
The purpose of our study was to investigate whether the variation in motor performance 
in children treated with VCR for ALL, was related to the presence of polymorphisms in 
genes involved in the metabolism of VCR, i.e. CYP3A5 and the toxicity of VCR i.e. 
MDR-1 and MAPT.
METhODS
Patients
The study was conducted at the paediatric oncology department of the Erasmus MC 
Sophia Children’s Hospital in the Netherlands. Approval of the Medical Ethical Commit-
tee was obtained. Written informed consent according to the Helsinki agreement was 
obtained from all parents.
Eligibility criteria were as follows:
- being in complete remission after treatment for acute lymphoblastic leukemia
- at least one year after completion of therapy at time of testing
- aged 4-12 years at time of testing (because the test used to measure motor perfor-
mance is validated for this age category)
Children who attended special education were excluded, as cognitive impairment is 
known to influence results of the motor performance test.
DNA isolation
DNA was isolated from EDTA blood using the Magnapure LC system (Roche).
CYP3A5 and MDR-1 analysis
For a 50-µl PCR, we used about 10 ng of genomic DNA. The PCR mixture contained 1X 
buffer [10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl2, 50 mM KCl, and 10 mg/L gelatin 
(Perkin-Elmer)], 0.2 mM each of the deoxynucleotide triphosphates (Roche), and 1.25 
U of Amplitaq Gold (Perkin-Elmer). For the CYP3A5*3 analysis, 40 pmol of primers 
P1 (5’-CATGACTTAGTAGACAGATGAC-3’) and P2 (5’-GGTCCAAACAGGGAAGAAA-
TA-3’) was used, with the underlined nucleotide presenting a mismatch with the CYP3A5 
sequence, creating a restriction site in the PCR product. PCR conditions were: 7 min at 
94°C; 40 cycles of 1 min at 94°C, 1 min at 57°C and 1 min at 72°C; and finally 7 
min at 72°C. The 2936 bp PCR product (10 µl) was digested with Ssp1 (New England 
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Biolabs) in a total volume of 15 µl for 2 h at 37°C and subsequently analyzed on a 3% 
agarose/Tris-borate-EDTA gel with ethidium bromide staining.
The fragments obtained for the CYP3A5*1 allele were 148, 125 and 20 bp; for the 
CYP3A5*3 variant allele, the fragments obtained were 168 and 125 bp.
For the MDR-1 C3435T genotyping, 40 pmol of primers P3 (5’-CATGCTCCCAGGCT-
GTTTAT-3’) and P4 (5’-GTAACTTGGCAGTTTCAGTG-3’) were used. PCR conditions 
were: 7 min at 94°C; 35 cycles of 1 min at 94°C, 1 min at 60°C and 1 min at 72°C; 
and finally 7 min at 72°C. The 340 bp PCR product (10 µl) was digested with DpnII 
(New England Biolabs) in a total volume of 15 µl for 2 h at 37°C and subsequently 
analyzed on a 3% agarose/Tris-borate-EDTA gel with ethidium bromide staining. The 
fragments obtained for the 3434C allele were 172, 90, 78 bp, for the 3435T variant 
allele the fragments were 262 and 78 bp. For the MDR-1 C1236T genotyping, 40 pmol 
of primers P5 (5’-CCTGACTCACCACACCAATG -3’) and P6 (5’-TATCCTGTGTCTGT-
GAATTGCC-3’) were used. PCR conditions were: 7 min at 94°C; 35 cycles of 1 min 
at 94°C, 1 min at 55°C and 1 min at 72°C; and finally 7 min at 72°C. The 370 bp 
PCR product (10 µl) was digested with HaeIII (New England Biolabs) in a total volume 
of 15 µl for 2 h at 37°C and subsequently analyzed on a 3% agarose/Tris-borate-EDTA 
gel with ethidium bromide staining. The fragments obtained for the 1236C allele were 
272, 63, 35 bp, for the 1236T variant allele the fragments were 272, and 98 bp. The 
MDR-1 G2677A/T genotyping was performed using Taqman allelic discrimination as-
says on the ABI Prism 9700 HT Sequence detection system. For this tri-allelic variant, two 
separate assays were designed, one detecting G2677A and one detecting G2677T. 
Each assay consisted of two allele-specific minor groove binding (MGB) probes, labeled 
with the fluorescent dyes VIC and FAM. The primer and probe sequences, designed by 
Applied Biosystems by their Assay-by-Design service are listed in Table I. Polymerase 
Table I Taqman primer and probe sequences for MDR-1 G2677A/T
SNP Sequence
MDR-1 G2677A Forward primer AATACTTTACTCTACTTAATTAATCAATCATATTTAGTTTGACTCA
Reverse primer GTCTGGACAAGCACTGAAAGATAAGA
VIC probe TTCCCAGCACCTTC
FAM probe CTTCCCAGTACCTTC
MDR-1 G2677T Forward primer CTTAGAGCATAGTAAGCAGTAGGGAGT
Reverse primer GAAATGAAAATGTTGTCTGGACAAGCA
VIC probe TTCCCAGCACCTTC
FAM probe TTCCCAGAACCTTC
The positions of the SNPs are underlined.
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chain reactions (PCR) were performed in a reaction volume of 10µl, containing assay-
specific primers, allele-specific Taqman MGB probes, Abgene Absolute QPCR Rox Mix 
and genomic DNA (1 ng). The thermal profile consists of an initial denaturation step at 
95°C for 15 minutes, followed by 40 cycles of denaturation at 92°C for 15 seconds 
and annealing and extension at 60°C for 1 minute. Genotypes were scored by measur-
ing allele-specific fluorescence using the SDS 2.2.2 software for allelic discrimination 
(Applied Biosystems).
MAPT mutation analysis
The 13 coding exons including intron-flanking regions of the microtubule-associated pro-
tein MAPT gene were amplified using PCR primers designed in Oligo 6.22 (Molecular 
Biology Insights) and listed in Table II. PCR conditions were optimized per exon, but in 
general samples were heated to 95°C for 5 min and amplified for 14 cycles at 94°C for 
20 s, 63°C for 60 s (decrease of 0.5°C per cycle) and 72°C for 60 s. Subsequently, 
a second amplification was initiated for 20 cycles at 94°C for 20 s, 56°C for 60 s and 
72°C for 60 s, the program is completed by a final extension step of 5min 72°C. PCR 
reactions were performed in 30 µl volumes containing 36 ng genomic DNA, 1x PCR 
buffer (Integro), 2 mM MgCl2 (Applied Biosystems), 200 µM of each dNTP (Promega), 
300 µM of forward and reverse primer (Eurogentec) and 0.75 U ThermoPerfect Taq 
polymerase (Integro). Samples were denatured at 95°C for 5 min and slowly cooled 
down to 4°C to facilitate heteroduplex formation. Aliquots of 10µl of each PCR product 
were injected under temperature and acetonitrile gradient conditions, optimized per 
exon (listed in Table III) and subsequently analysed for the presence of mutations by DH-
PLC (WAVETM-system 2100/3500HT, Transgenomic). Abnormal products were identified 
by examination of the WAVE patterns using WavemakerTM software (Transgenomic). PCR 
products suspected to be abnormal were subjected to bidirectional sequence analysis 
as described by the protocol of BigDye terminator v1.1 (Applied Biosystems) followed 
by automated sequencing on the ABI PRISM® 3100 Genetic Analyzer (Applied Bio-
systems). Polymorphism A68504G (exon 1), A80659G (intron 3), C90092T (exon 
5), T96360C (intron 7), T96214C (exon 7), T102787C (exon 9) were defined as 
haplotype A, based on linkage analysis in Haploview 3.32. Linkage was defined as 
r2≥ 0.8. The other polymorphisms found were not linked to the previous mentioned are 
defined as haplotype B.
Treatment
Children with ALL were treated according to the ALL-9 protocol of the Dutch Childhood 
Oncology Group: this is almost identical to the previously used protocol ALL-6 25. The 
VCR dose is 2.0 mg/m² with a maximum of 2.5 mg; cumulative VCR doses in the above 
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mentioned treatment protocol varies from 62.0 mg/m² in the high-risk protocol to 68.0 
mg/m² in the non high-risk protocol.
Assessment of motor performance
Motor performance was measured using the Dutch version of the Movement Assess-
ment Battery for Children (movement-ABC) 26,27. The movement-ABC consists of a series 
of eight standardized tasks divided in three subsections: hand function, ball skills and 
balance skills. Tasks vary with age and are designed to resemble every day activities 
Table II Primers microtubule-associated protein tau (MAPT)
Exon Primer Sequence Temp. (°C)
 used for dHPLC
1
 
forward
reverse
5’-
5’-
CAGGGAGGCTGAGATCTG
GTGCATGGCTGTCCACTA
-3’
-3’
62
 
2
 
forward
reverse
5’-
5’-
CCACAGGGAGCGATTTT
AAGCACGGCTAAGCACA
-3’
-3’
63
 
3
 
forward
reverse
5’-
5’-
GGTGGATCTCGGTGGTT
GCCCCACAGGAGGATAA
-3’
-3’
62
 
4
 
forward
reverse
5’-
5’-
ACCCCCCTTCATTTGC
TCCCAGGCTGGACAAG
-3’
-3’
57
 
5-1
 
forward
reverse
5’-
5’-
CACCACTGCGTATCTCCAC
CTGGGATCTCTGTGGAAACT
-3’
-3’
64
 
5-2
 
forward
reverse
5’-
5’-
CTCCCTGTGGATTTCCTC
AGGCCTGGAAGCTCAGT
-3’
-3’
64
 
6
 
forward
reverse
5’-
5’-
GCTGGCTTTCTGTGAACA
AACCTGCCAACTGCTCTT
-3’
-3’
57
 
7
 
forward
reverse
5’-
5’-
CCTCCATGTGCTGACTTTTAT
CTTAGGAGCTGCTGCTATGAG
-3’
-3’
58
 
8
 
forward
reverse
5’-
5’-
AGCCACGTTTTGAGTCAAG
GGACTGAGAAGGCAATGAA
-3’
-3’
60
 
9
 
forward
reverse
5’-
5’-
CCACCCACTCGAGTCCT
AGGGGACTGGGGTGTTA
-3’
-3’
64/65
 
10
 
forward
reverse
5’-
5’-
TGCCAATGCCGAAAGTG
TTCACCCAGAGGTCGC
-3’
-3’
60
 
11
 
forward
reverse
5’-
5’-
GGCCTGGGCTTACACA
GCTCCCGCAAGTTTCA
-3’
-3’
58
 
12 forward
reverse
5’-
5’-
TGGCAAGATGCTCTTGTG
GACCAGCCTTTGTCCACT
-3’
-3’
60
 
13
 
forward
reverse
5’-
5’-
GGCAGGGCTGGTCTTT
GGGCCGGGTCATTATT
-3’
-3’
61
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of children. The total score of the movement-ABC is transformed into a percentile score 
by age-related norms. A score below the 5th percentile indicates impaired motor perfor-
mance, between 5th and 15th percentile is borderline and higher than the 15th percentile 
is normal. The child’s performance on each of the subsections is also expressed as either 
below or above the 15th percentile. Validity of the movement-ABC to test motor ability in 
children has been shown before 28.
Table III Aberrations found in MAPT
exon/
intron
SNPa
position
alteration position on
chromosome 
17
amino acid
substitution
% in patient
 group
corrected for
extra patients
based on 
rs1800547c
dbSNP numberd
missense
5 89673 A>G 41416697 Q230R 10,8% (4/37) unknown
5 89837 G>A 41416860 D285N 38,5% (15/39) unknown
5 89850 T>C 41416873 V289T 38,5% (15/39) unknown
5 90092 C>T 41417115 R370W 38,5% (15/39) 36,4% (24/66) rs17651549
7 96196 T>C 41423219 H441Y 66,7% (26/39) rs2258689
7 96124 T>C 41423237 S447F 38,5% (15/39) 36,4% (24/66) rs10445337
silent
1 68504 A>G 41395527 no 
translationb
38,5% (15/39) 36,4% (24/66) rs17650901
5 89839 C>T 41416862 D285D 30,7% (12/39) unknown
9 102787 T>C 41429810 N572N 35,1% (13/37) 36,4% (24/66) rs17652121
9 102832 G>A 41429855 P587P 5,4% (2/37) rs11568305e
intronic
3 80659 A>G 41407682 36,4% (24/66) 36,4% (24/66) rs1800547
7 96322 A>G 41423345 28,2% (11/39) unknown
7 96360 T>C 41423383 28,2% (11/39) 36,4% (24/66) rs17651754
9 102947 G>A 41429970 8,1% (3/37) unknown
11 120594 G>A 41447623 33,3% (13/39)  unknown
mutation which could not be identified by sequencing
amplicon of exon 2
amplicon of exon 9
amplicon of exon 13
a position relative to Ensembl entry: ENSG00000186868 genomic sequence
b this SNP was located in 3’UTR, no amino acid translation 
c extra 27 patients were tested for rs1800547, because linkage was proven between: rs17651549/
rs10445337/rs17652121/rs1800547 and rs17651754, they were all subjected for analysis
d reference number in dbSNP database, numbers in bold are linked together based on haploview, r2=1,0
e was not shown in haploview and was not analyzed for linkage
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Statistics
The SPSS statistical package (version 12.0.1) was used to analyse the data. Group dif-
ferences were calculated using the Mann Whitney and Kruskal-Wallis tests. Comparison 
of ordinal categorical scores between individuals with MAPT haplotype A and B was 
carried out with the linear-by-linear association test.
RESULTS
Patients
A total number of 34 survivors of ALL, 18 boys (53%) and 16 girls (47%), participated 
in the study. Mean age at follow-up was 7.8 years (sd ± 2.2), mean age at diagnosis 
3.7 years (± 2.1) and mean time since completion of treatment 1.9 years (± 0.5). Nine 
children had been treated with the ALL high-risk protocol, the other 25 children with the 
protocol for non high-risk patients.
Distribution of individual SNPs and haplotypes
Thirty-four patients were genotyped for the CYP3A5*3 allele, detecting twenty-two indi-
viduals with CYP3A5 *3/*3 (65%) and 12 individuals *1/*3 (35%).
For the MDR-1 analysis at position 3435, we found 11 individuals 3435TT (32%); 19 
individuals 3435CT (56%) and 4 individuals 3435CC (12%). For the SNP at position 
2677, both the G2677T and the G2677A substitutions were determined, yielding 
9 patients 2677 TT (27%), 14 patients 2677GT (43%), 2 patients 2677GA (6%), 8 
patients 2677GG (24%); one result was inconclusive. These genotypings resulted in 2 
carriers of haplotype 1/1 (6%) and 5 carriers of haplotype 1/2 (15%) as described by 
Johne 19.
For the C1236T SNP of the MDR-1 gene, 8 patients were 1236TT (25%), 14 patients 
were 1236CT (44%) and 10 patients were 1236CC (31%). Two results were inconclu-
sive.
The MAPT analysis revealed a similarity in results for a number of patients (Table III). Hap-
loview linkage analysis revealed that SNP’s in exon 1,2,3,4,5 and 7 were closely linked 
(r² =1.0) and hence we defined this as haplotype A. The other SNP’s were labelled as 
haplotype B. Ten patients were haplotype A carriers (29%) and 24 haplotype B (71%); 
one result was inconclusive. The distribution of individual SNPs and haplotypes is shown 
in Table IV.
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Table IV Distribution of SNPs
Case
number
CYP3A5
C1236T
MDR-1
G2677A/T
MDR-1
C3435T
MDR-1 MAPT
haplotype
1 *1/*3 CC GG CC B
2 *3/*3 CT TT TT B
3 *1/*3 CC GA CC B
4 *3/*3 TT TT TT B
5 *3/*3 CT GT TT A
6 *3/*3 TT TT TT A
7 *3/*3 CC GG CT B
8 *1/*3 CT GT CT A
9 *3/*3 CT GT CT B
10 *3/*3 - - CT A
11 *3/*3 CC GG CT A
12 *1/*3 TT TT TT A
13 *3/*3 CC GG CT A
14 *3/*3 CT GT CT B
15 *3/*3 TT TT TT B
16 *3/*3 CT GT CT B
17 *1/*3 TT TT TT B
18 *3/*3 CC GG CT B
19 *3/*3 CC GA CC B
20 *3/*3 CT GT CT B
21 *3/*3 CT GT CT B
22 *3/*3 CC GG CT B
23 *3/*3 CT TT TT B
24 *3/*3 CC GG TT B
25 *1/*3 - GT CT B
26 *3/*3 CC GG CC A
27 *1/*3 TT TT CT B
28 *1/*3 TT GT CT B
29 *3/*3 TT TT TT A
30 *1/*3 CT GT CT B
31 *1/*3 CT GT TT B
32 *1/*3 CT GT CT B
33 *1/*3 CT GT CT B
34 *3/*3 CT GT CT B
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Motor performance scores
The scores on the movement-ABC test for motor performance (m-ABC) were converted 
into percentiles. The median percentile score of the total group was 35.
The difference in percentile scores on the m-ABC between CYP3A5 *3/*3 and CY-
P3A5*1/*3 genotypes was not statistically significant (p= 0.49, Figure 1).
Percentile scores on the m-ABC were not significantly affected by the MDR-1 SNPs 
C3435T (p= 0.87, Figure 2a), G2677A/T (p=0.28, Figure 2b) or C1236T (p=0.66, 
Figure 2c). The data were also analysed using haplotypes as defined by Johne 19. There 
was no significant difference in percentiles score between 3435C/2677G carriers 
(haplotype 1/1), 3435T/2677G carriers (haplotype 1/2) and others (p=0.56).
There was no significant difference in percentile scores on the m-ABC between MAPT 
haplotype A and haplotype B carriers (p=0.47, Figure 3).
DISCUSSION
This study did not provide evidence that CYP3A5, MDR-1 or MAPT genetic polymor-
phisms affect motor performance in children who have been treated for ALL with VCR 
containing chemotherapy.
We hypothesised that the presence of CYP3A5*3/*3 would increase VCR toxicity and 
result in lower scores on the movement-ABC motor performance test, but our data did not 
support this. However, because our patient cohort only had CYP3A5*1/*3 expressers, 
no conclusions about the effect of CYP3A5*1/*1 individuals could be made. This pro-
 
Figure 6/1  Movement-ABC percentile scores of carriers of the CYP3A5 *3/*3 and 
CYP3A5 *1/*3 allele 
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 Figure 1 Movement-ABC scores of motor performance, in percentiles, of children with CYP3A5 *3/*3 and 
CYP3A5 *1/*3 genotypes. The horizontal bars depict the median values.
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Figure 6/2a Movement-ABC percentile scores of MDR-1 C3435T carriers 
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Figure 2a Movement-ABC scores of motor performance, in percentiles, of children with MDR-1 3435TT, 
3435CT, and 3435CC genotypes. The horizontal bars depict the median values.
 
Figure 6/2b Movement-ABC percentile scores of MDR-1 G2677A/T carriers 
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Figure 2b Movement-ABC scores of motor performance, in percentiles, of children with MDR-1 2677TT, 
2677GT, 2677GA, 2677GG genotypes. The horizontal bars depict the median values.
 
Figure 6/2c Movement-ABC percentile scores of MDR-1 C1236T carriers 
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Figure 2c Movement-ABC scores of motor performance, in percentiles, of children with MDR-1 1236TT, 
1236CT and 1236CC genotypes. The horizontal bars depict the median values.
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hibited us of comparing motor performance between the two extremes of the spectrum, 
i.e. CYP3A5 *3/*3 versus CYP3A5*1/*1.
The MDR-1 gene, encoding the efflux pump P-glycoprotein (P-gp), affects the distribution 
of drugs such as VCR. P-gp has been shown to influence biliary clearance of VCR 14,15,29. 
P-gp is located in the blood-nerve barrier and can limit VCR exposure of the nerves 30,31. 
If P-gp is under-expressed or has lower activity, nerve exposure to VCR and the incidence 
of polyneuropathy may increase and affect motor performance outcome. MDR-1 SNPs 
associated with VCR pharmacokinetics are C3435T and G2677T/A, but in our patients 
we did not find an effect on motor performance. Plasschaert et al described a negative 
effect of 3435C/2677G carriers and a possible positive effect of 3435T/2677G car-
riers on the elimination half-life of VCR 20. We hypothesised that these haplotypes would 
affect motor performance in a similar way, but our data did not support this. However, 
as there were only two 3435C/2677G and five 3435T/2677G carriers in our cohort, 
numbers might have been too small to reach a definite conclusion.
Polyneuropathy as a side effect of VCR occurs because it damages microtubules in the 
axonal part of the nerves, resulting in impaired axonal transport and loss of nerve func-
tion. The MAPT promotes microtubule assembly and stability in the axonal compartments 
of neurons 32. Theoretically, under-expression of MAPT may compromise microtubule 
stability thereby increasing the incidence and severity of polyneuropathy. Our hypothesis 
was that MAPT haplotype A carriers would perform less well on the movement-ABC test 
compared to haplotype B, but this was also not supported by our data.
 
Figure 6/3 Movement-ABC percentile scores for MAPT haplotype A and  
haplotype B carriers  
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Figure 3 Movement-ABC scores of motor performance, in percentiles, of children with MAPT haplotype A 
and haplotype B. The horizontal bars depict the median values.
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In conclusion, our study did not show that polymorphisms of CYP3A5, MDR-1 or the 
MAPT gene influenced motor performance in children who had been treated for ALL with 
VCR.
However, the number of cases studied was relatively small limiting the power to study the 
effect of combinations of polymorphisms in different genes. Very large studies would be 
needed to analyse such a multifactorial cause of differences in motor performance.
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ABSTRACT
Reduced bone mineral density (BMD), altered body composition, impaired motor perfor-
mance and passive ankle dorsiflexion are side effects of acute lymphoblastic leukemia 
(ALL) treatment.
At diagnosis we randomised 51 ALL patients (median age: 5.4 years) into a group 
receiving a two-year exercise programme or a control group, to investigate whether ex-
ercise could prevent these side effects. BMD of total body (BMDTB), lumbar spine (BMDLS) 
and body composition were measured using dual energy X-ray absorptiometry, motor 
performance with Bayley Scales of Infant Development or Movement-ABC, and passive 
ankle dorsiflexion with a goniometer. The investigator was blinded to the randomisation. 
Repeated measurements analysis (ANOVA) was used.
Body-fat increased equally during treatment in both groups. One year after cessation of 
therapy more rapid decline of excessive body fat was observed in the intervention group 
than in the controls (p=0.01). Lean body mass, BMDTB and BMDLS of both groups de-
creased equally during treatment and increased equally thereafter. Both groups showed 
a similar decrease in passive ankle dorsiflexion and motor performance during treatment. 
Adherence to the intervention programme varied considerably.
The exercise programme was not more beneficial in preventing reduction in BMD, mo-
tor performance and passive ankle dorsiflexion than standard care, most likely due to 
unsatisfactory compliance.
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Intervention programme
INTRODUCTION
Because the survival rate of ALL has improved, preventing side effects of chemotherapy 
has become increasingly important. Several studies have shown that motor performance, 
peripheral muscle strength and passive ankle dorsiflexion in children treated for ALL was 
impaired during treatment and also after cessation of chemotherapy1-4. These problems 
were mainly attributed to vincristine-induced neuropathy. Moreover, treatment protocols 
for ALL contain a considerable amount of prednisone and/or dexamethasone. This may 
cause steroid-associated myopathy with weakness of proximal musculature and muscle 
atrophy leading to a decreased lean body mass (LBM) 5. In addition, corticosteroids 
and methotrexate (MTX) are known to cause reduction of bone mineral density (BMD). 
Several studies have shown that BMD is already lower at diagnosis of ALL and decreases 
further during the two-year treatment period6,7. Although a decreased BMD is unlikely to 
affect motor performance directly, it is associated with an increased fracture risk8. Studies 
investigating BMD in long-term survivors of childhood ALL show conflicting results9-13. In 
general, BMD of patients treated without cranial irradiation shows a tendency to improve 
after cessation of therapy8,14. Several animal studies in which mechanical loads were 
applied showed that the crucial factor in stimulation of bone acquisition is the magnitude 
rather than the number of repetitions of the load applied15,16. Therefore, short-burst high-
intensity activities might be effective to enhance BMD during childhood17-20. However, 
no studies have been performed to investigate this effect of exercise on BMD during 
treatment of childhood ALL.
Because vincristine-related neuropathy causes weakness in the dorsiflexors of the foot, 
children are at risk for developing a plantigrade contracture of the ankle. Wright et al. 
found positive effects of preventative education and physiotherapy consisting of stretch-
ing and strengthening exercises on passive ankle dorsiflexion during treatment for ALL21. 
Another study reported positive effects of physical exercises on ankle dorsiflexion mobility 
and strength of knee extensors, but no improved functional outcome was found22.
In the current prospective randomised study in childhood ALL we investigated whether an 
exercise programme starting at onset and continued during 2-year treatment for ALL has 
a beneficial effect on BMD, body composition, motor performance and passive ankle 
dorsiflexion.
MATERIALS AND METhODS
Patients
Between April 2001 and September 2004 the study was conducted in Erasmus MC-So-
phia Children’s Hospital Rotterdam, the Netherlands. Children with ALL aged 1-18 years 
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that did not have cognitive impairment and had good command of the Dutch language 
were eligible. Clinical data (age, gender, immunophenotype of leukemia, fractures) were 
obtained from the medical records. The Medical Ethical Committee approved the study. 
Written informed consent according to the Helsinki agreement was obtained from all 
parents and from patients ≥ 12 years.
Chemotherapy treatment
Patients were treated according to the ALL-9 protocol of the Dutch Childhood Oncol-
ogy Group (DCOG), which was identical to the previously used ALL-6 protocol for the 
non-high-risk (NHR) patients23. The ALL-9-NHR protocol started with induction therapy 
including dexamethasone and vincristine, followed by high-dose MTX courses and main-
tenance therapy with 6-mercaptopurine/MTX plus vincristine/dexamethasone pulses. 
Patients were treated according to the high-risk (HR) protocol when they met one of the 
following criteria: white blood cell count ≥50x109, T-cell immunophenotype, mediastinal 
mass, involvement of the central nervous system, infiltration of the testes, t(9;22) or BCR-
ABL gene rearrangement, t (4;11) or translocations involving 11q23 with MLL gene-re-
arrangements. High-risk ALL patients received anthracyclines during induction treatment, 
higher doses of MTX during central-nervous-system prophylaxis and they received two 
additional intensification courses before start of maintenance therapy.
Randomisation
Randomisation into the intervention or the control group was carried out in randomly 
permuted blocks of randomly chosen size, using sealed envelopes prepared by the statis-
tician. The research nurse informed parents into which group their child was randomised. 
The investigators and treating physicians were blinded for the randomisation.
Intervention and standard care
The intervention group received an initial session and 6-weekly follow-up sessions with the 
hospital-based paediatric physiotherapist, throughout the two-year treatment period. The 
initial session comprised of education regarding possible motor problems resulting from 
chemotherapy and general measures to ensure an optimum level of motor functioning. 
In addition an exercise programme was introduced, consisting of exercises to maintain 
hand and leg function, stretching exercises to maintain ankle dorsiflexion mobility and 
short-burst high-intensity exercises (e.g. jumping) to prevent reduction in BMD. Exercises 
to maintain hand and leg function had to be performed once a day and stretching and 
jumping exercises twice daily. The 6-weekly follow-up sessions involved an evaluation of 
the child’s main motor skills (walking, running, jumping), discussion and adjustment of the 
exercise programme if necessary. Passive ankle dorsiflexion was monitored and if < 5º 
beyond the neutral position, patients received plaster of Paris splints overnight. In case 
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of concern regarding a child’s motor ability they would be referred to a local paediatric 
physiotherapist for additional treatment. Follow-up sessions with the hospital-based phys-
iotherapist always coincided with regular visits to the oncology outpatient department.
Standard care for the control group included neither an initial session nor any pre-
scheduled follow-up sessions with the hospital-based physiotherapist. If child or parents 
reported motor problems to the treating physician a referral to a local paediatric physio-
therapist was allowed.
On cessation of chemotherapy parents of children in both groups received a short ques-
tionnaire. All parents were asked whether they had valued testing of motor performance 
by the investigator. Parents of children in the intervention group were questioned about 
adherence to the exercise programme.
End points
At diagnosis, 32 weeks after diagnosis, one year after diagnosis, on cessation of treat-
ment (two years after diagnosis) and one year after cessation of therapy the following 
end points were measured: anthropometric data (height, weight, body mass index (BMI)), 
body composition (LBM and percentage body fat), BMD (primary end point) of the total 
body (BMDTB), and lumbar spine (BMDLS). Motor performance (primary end point) and 
passive ankle dorsiflexion were assessed at diagnosis, following induction therapy (six 
weeks after diagnosis), one year after diagnosis and on cessation of treatment.
Anthropometry, body composition and BMD
Height was measured using a Harpenden stadiometer and weight using a standard clini-
cal balance. Body mass index (BMI) was calculated as weight/height2. In patients aged 
4-19 years body composition parameters, BMDTB, and BMDLS were measured using dual 
energy X-ray absorptiometry (DEXA; Lunar DPX-L, Madison, WI). To correct for bone size, 
bone mineral apparent density of the lumbar spine (BMADLS) was calculated as BMADLS= 
BMDLS*[4/(π*width)]. The DEXA of total body provided estimates of body composition: 
lean body mass (LBM) which consists mainly of muscle mass and percentage of body 
fat. All results were compared with those of Dutch healthy children and expressed as 
standard deviation scores (SDS) 24,25.
Skeletal complications
Fractures had to be confirmed on X-ray and symptomatic osteonecrosis by magnetic 
resonance imaging.
Motor performance
For children < 3.5 years motor performance was measured using the motor scale of the 
Dutch Bayley Scales of Infant Development (BSID-II) and for children aged ≥ 4 years the 
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Dutch version of the Movement Assessment Battery for Children (movement-ABC) was 
used26,27. The motor scale of the BSID-II consists of several motor tasks and the total 
number accomplished by the child is converted into a SDS. The movement-ABC has eight 
standardized tasks divided in three subsections: hand function, ball skills and balance 
skills. The total score of the movement-ABC is transformed by age-related norms into a 
percentile score.
Passive ankle dorsiflexion
To measure passive ankle dorsiflexion a standardised position was used: supine position, 
with the knee extended. A range of motion past neutral position had a positive notation 
and less than neutral was negative. The lower of the two passive ankle dorsiflexion 
values (preferred and non-preferred side) will determine the level of impairment and was 
therefore used for analysis.
Statistical analysis
The Mann-Whitney U-test/χ2-test was used to compare patient characteristics of the inter-
vention and control groups. Motor performance of the whole study group was compared 
with reference values using the one-sample T-test. Within-group differences in motor per-
formance and passive ankle dorsiflexion mobility were analysed using a paired T-test. 
These statistical analyses were carried out with SPSS for Windows version 11.0.1 (SPSS 
Inc., Chicago, IL, USA). Differences between the two groups in changes of endpoints 
during the two-year treatment period (Δ1) and from cessation of chemotherapy during 
the first year after cessation (Δ2) were analysed using repeated measurements analysis 
(SAS PROC MIXED SAS Institute Inc., Cary, North Carolina, USA), with an unstructured 
repeated covariance type. P-values less than 0.05 (two-sided) were considered statisti-
cally significant. Power calculations resulted in entering 50 children in the study. All 
analyses were carried out according to the intention-to-treat principle; for children who 
did not complete the study data prior to elimination were included.
RESULTS
Patients
During the inclusion period 67 children were eligible of which 12 declined and 4 were 
not randomised. There were no significant differences in age at diagnosis (median age: 
5.4 vs. 4.8 year, p=0.41), gender (50% vs. 59% male, p=0.53) and immunophenotype 
of ALL (80% vs. 75% B-lineage ALL, p=0.73) between patients who did or did not enter 
the randomised study.
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Figure 1 shows the study profile. Patient characteristics of the intervention and the control 
group at diagnosis are shown in Table I.
Anthropometry and body composition
Height, weight and BMI
At diagnosis, height, weight and BMI were not significantly different between the two 
groups (Table II). BMI significantly increased during the two years of chemotherapy in the 
intervention group (Δ1BMI = 1.53 SDS) and in the control group (Δ1BMI = 1.38 SDS); 
this increase did not significantly differ between both groups (p=0.69). One year after 
cessation of treatment, BMI had decreased towards normal values of healthy peers in 
both intervention and control group (Δ2BMI = -0.95 SDS vs. Δ2BMI = -0.47 SDS), but this 
change was significantly more pronounced in the intervention group (p=0.026) (Figure 
 
 75 assessed for eligibility 8 excluded 
 
   4 with Down syndrome 
   2 because of a linguistic barrier 
   1 treated with Esphall protocol 
   1 treated with CNSL-initial-8406 
67 enrolled16 not randomly assigned 
 
   12 did not give consent  
         (refusal by parents/child) 
     4 not randomized 
51 randomly assigned
26 randomly assigned to receive standard care25 randomly assigned to receive the 
preventative physiotherapy programme  
5 did not complete the study 
 
   1 switched protocol due to psychosis 
   4 relapsed during treatment of which 2 died 
5 did not complete the study 
 
  1 switched protocol due to pancreatitis 
  2 relapsed during treatment of which 1 died 
  1 relapsed within 1 year after stop treatment 
  1 died due to infection 
          
21 in main analysis 
 
20 in main analysis 
Figure 7/1 Study profile 
Figure 1. Study profile
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2A). On cessation of chemotherapy and one year after cessation of therapy there were 
no significant differences between the groups in height, weight and BMI (Table II).
Body fat
At diagnosis there was no significant difference between the groups in percentage of body 
fat. During treatment there was no significant difference in the change of body fat percent-
age between the intervention group and that in the control group (Δ1fat% = 1.04 SDS vs. 
Δ1fat% = 1.56 SDS, p=0.25). One year after cessation of chemotherapy the percentage 
of body fat had decreased in the intervention group (Δ2fat% = -1.08 SDS, p<0.001) and 
in the control group (Δ2fat% = -0.49 SDS, p=0.001). The decrease was more prominent 
in the intervention group than in the control group (p=0.013) (Figure 2B).
Table I Patient characteristics of the intervention group and the control group at diagnosis.
Intervention group Control group P-value
Gender
 Boys
 Girls
14 (56%)
11 (44%)
16 (62%)
10 (38%)
0.69
Age (years)
 Median
 Minimum
 Maximum
 5.3
 1.3
15.6
 6.2
 1.7
17.1
0.52
Immunophenotype
 B-lineage
 T-lineage
21 (84%)
 4 (16%)
20 (77%)
 6 (23%)
0.73
Protocol
 Non high risk
 High risk
19 (76%)
 6 (24%)
15 (58%)
11 (42%)
0.17
Table II Anthropometry and body composition at diagnosis, on cessation of chemotherapy and 1 year after 
cessation of chemotherapy
Diagnosis Cessation of chemotherapy 1 Year after cessation of 
chemotherapy
Median SDS Intervention 
group
Control 
group
P-value Intervention 
group
Control 
group
P-value Intervention 
group
Control 
group
P-value
Height -0.11 0.10 0.66 -0.87 -0.27 0.16 -0.47 -0.07 0.92
Weight -0.40 -0.09 0.76  0.54 0.51 0.93 -0.10 0.36 0.51
Body mass index -0.33 -0.38 0.86  1.20 1.00 0.52  0.26 0.54 0.4
Percentage of body fat  0.47 -0.22 0.12 1.51 1.34 0.6  0.44 0.85 0.32
Lean body mass -0.46 -0.66 0.57 -1.07 -0.78 0.37 -0.78 -0.56 0.48
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LBM
At diagnosis there was no significant difference in LBM between the intervention group 
and the control group. We found no differences between the two groups in decline of 
LBM from start to cessation of treatment (intervention group: Δ1LBM = -0.61 SDS vs. con-
trol group: Δ1LBM = -0.12 SDS, p=0.16). One year after treatment LBM had increased 
equally in both groups (intervention group: Δ2LBM = 0.29 SDS vs. control group: Δ2LBM 
= 0.22 SDS, p=0.66) (Figure 2C).
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Figure 7/2 Development of body composition of the intervention and the control  
group  
Figure 2. Development of body composition of the intervention and the control group. 
Values are expressed as mean +/− standard error of the mean. Abbreviations: SDS = standard deviation 
score, BMI = body mass index, LBM = lean body mass. Results of the intervention group: dotted line. Results 
of the control group: continuous line.
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Bone mineral (apparent) density
At diagnosis there were no significant differences between the intervention group and 
the control group in BMDTB (-0.10 SDS vs. –0.18 SDS, p=0.87), BMDLS (-0.42 SDS vs. 
-0.96 SDS, p=0.22) and BMADLS (0.14 SDS vs. –0.48 SDS, p=0.09).
Between start and cessation of treatment BMDTB decreased significantly in both groups 
(intervention group: Δ1BMDTB = -0.75 SDS, p=0.03 and control group: Δ1BMDTB = 
-0.96 SDS, p=0.003). The decrease of BMDTB did not differ between both groups 
(p=0.65). One year after discontinuation of treatment BMDTB had recovered in both 
groups (intervention group: Δ2BMDTB = 0.42 SDS, p=0.004 and control group: Δ2BMDTB 
= 0.35 SDS, p=0.002). This recovery of BMDTB was not different between both groups 
(p=0.70) (Figure 3A).
BMDLS did not change in either group during treatment (intervention group: Δ1BMDLS =
-0.15 SDS, p=0.69 vs. control group: Δ1BMDLS = -0.04 SDS, p=0.90) nor one year 
after cessation of chemotherapy (intervention group: Δ2BMDLS = 0.10 SDS, p=0.54 vs. 
control group: Δ2BMDLS = 0.14 SDS, p=0.30) (Figure 3B). In addition, after correction 
for bone size, we found no difference between the intervention and control group in the 
development of the BMD of the lumbar spine during chemotherapy (Δ1BMADLS = -0.66 
SDS vs. Δ1BMADLS = -0.36 SDS, p=0.47) or during the year after cessation of therapy 
(Δ2BMADLS = 0.12 SDS vs. Δ2BMADLS = 0.04 SDS, p=0.77) (Figure 3C).
Skeletal complications
During the study period seven children in the intervention group and three controls sus-
tained fractures (29% vs. 12%, p=0.17). Each group contained one patient with 2 
fractures.
Motor performance
At diagnosis motor performance of the patients was significantly impaired compared to 
healthy peers (-1.41 SDS, p<0.001). There was a trend to improvement in motor perfor-
mance of both groups combined from -1.41 SDS at diagnosis to -1.00 SDS at cessation 
of treatment (p=0.055). There was no significant difference between the intervention 
and control group in change of motor performance during the course of chemotherapy 
treatment (Δ1= 0.37 SDS vs. Δ1= 0.68 SDS, p=0.44) (Figure 4).
Passive ankle dorsiflexion
Mean passive ankle dorsiflexion of both groups combined changed significantly from 
9.1º (SD 4.6) at diagnosis to 4.2º (SD 5.8) at cessation of treatment (p=0.001). How-
ever, there was no significant difference in decrease in passive dorsiflexion mobility 
during the course of treatment between the intervention and control group (Δ1= -5.2º vs. 
Δ1= -4.6º, p=0.76) (Figure 5). In the intervention group five children had been supplied 
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Figure 7/3 Development of bone mineral density of total body and lumbar spine and of 
bone mineral apparent density of the lumbar spine of the intervention and control group  
Figure 3. Development of bone mineral density of total body and lumbar spine and of bone mineral 
apparent density of the lumbar spine of the intervention and control group. 
Values are expressed as mean +/− standard error of the mean. Abbreviations: SDS = standard deviation 
score, BMD-TB = bone mineral density of the total body, BMD-LS = bone mineral density of the lumbar spine, 
BMAD = bone mineral apparent density.
Results of the intervention group: dotted line. Results of the control group: continuous line.
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with night splints to maintain ankle dorsiflexion mobility versus none in the control group 
(p=0.017).
 
Figure 7/4 Development of motor performance scores of the intervention and the control 
group  
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Figure 4 Development of motor performance scores of the intervention and the control group
Values are expressed as mean +/− standard error of the mean. Abbreviation: SDS = standard deviation 
score. Results of the intervention group: dotted line. Results of the control group: continuous line.
 
Figure 7/5 Development of passive ankle dorsiflexion of the intervention  
and the control group  
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Figure 5 Development of passive ankle dorsiflexion of the intervention and the control group. 
Values are expressed as mean +/− standard error of the mean. The horizontal dotted line indicates the 
lower limit of normal mobility. Results of the intervention group: dotted line. Results of the control group: 
continuous line.
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Questionnaires
On completion of chemotherapy forty-two questionnaires were sent out: four were not 
returned leaving 38 available for analysis (19 in the intervention group, 19 controls). 
Ninety-five percent of all parents stated that they had appreciated the regular testing of 
motor performance and 84% of the parents in the intervention group appreciated the 
physiotherapy follow-up sessions. Adherence to the exercise programme in the interven-
tion group varied considerably: 11% of the parents performed exercises daily with their 
child, 37% more than once a week, 16% once weekly, and the other 36% less than once 
a week. Eight children in the intervention group (42%) and seven children in the control 
group (37%) had been referred to a local physiotherapist (p=0.52).
DISCUSSION
The present study showed no difference in change of BMI, body fat, LBM, BMD, motor 
performance or passive ankle dorsiflexion between childhood ALL patients who received 
the exercise programme and those who received standard care. Therefore, we conclude 
that the exercise programme was not more beneficial than standard care to prevent 
motor problems and reduction in bone mass during ALL treatment. However, increased 
BMI and body-fat of ALL patients in the intervention group did recover faster than in the 
control group during the year after cessation of chemotherapy, which may point to an 
educational effect of the intervention programme.
The results maybe explained by several reasons. First, although the study was based on 
a reasonable concept, it may not be possible to maintain a continuous 2-year exercise 
programme during childhood ALL treatment. In our cohort, disappointing adherence to 
the exercise programme seems to underscore this and may be important for the lack of 
impact on the primary end points. Another explanation might be that the intervention 
and control group were not well matched. However, the similarity of the groups in age, 
gender, body weight and immunophenotype or risk-group stratification does not support 
this hypothesis.
Scarce information is available in the literature on the value of regular exercise to prevent 
reduction in BMD, fractures, altered body composition, and impairment of motor perfor-
mance and passive ankle dorsiflexion during childhood ALL. The exercise programme 
aimed to diminish loss of BMD, muscle power and ankle mobility. According to the ret-
rospectively filled out questionnaires the adherence to the exercise programme was low. 
In order to promote adherence we ensured that parents - and if possible children - were 
educated regarding the side effects of chemotherapy, difficulties that could arise and the 
need for exercises. A large number of exercises were provided to make variation pos-
sible and the exercises had been constructed to fit into children’s normal daily activities. 
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The 6-weekly visits to the hospital-based paediatric physiotherapist always coincided 
with other appointments, but were missed regularly. Adherence to long-term programmes 
tends to be lower than to short-term interventions28 and exercising throughout the treat-
ment duration of 2 years may have been too long to remain motivated. Marchese et al. 
reported a positive effect of an exercise programme on active ankle dorsiflexion and 
knee extension strength. This may be explained by the fact that the intervention in their 
study lasted for four months only22. Whether this effect was maintained for the remainder 
of the treatment period is unknown. Progression of symptoms may have affected adher-
ence negatively29. Another important consideration is that also 37% of the children in 
the control group had received physiotherapy, albeit locally. It may well be that children 
who develop motor problems are referred on time and that standard care is already 
adequate.
Finally, because parents met regularly in the outpatient department, some exchange of 
information about the exercise programme between parents of children in the intervention 
group and of the controls cannot be ruled out.
Several animal studies showed that mechanical loads are a crucial factor in the stimula-
tion of bone acquisition15,16. In addition, studies in postmenopausal women30 and in 
healthy children17-20 have shown that exercise (including short-burst high-intensity activi-
ties) is an effective way to increase BMD. Therefore, we hypothesized that an exercise 
programme with short-burst high-intensity activities might impede the reduction in BMD 
in childhood ALL. However, the reduction of BMD was not prevented in our intervention 
group. Furthermore, we found no difference in number of patients with fractures between 
both groups.
Both BMI and body fat are in inverse relation to physical activity in healthy children31. 
We found no influence of the exercise programme on BMI or body fat during the treat-
ment period of two years, but the increased body fat was lost faster after cessation of 
chemotherapy in the intervention group. We cannot rule out an educational effect of the 
intervention, which may have resulted in a lifestyle change.
Motor performance of children with ALL was already decreased at diagnosis and was 
still decreased at cessation of chemotherapy. It is known that although motor perfor-
mance improves, it is still lower than in healthy peers two years after cessation of treat-
ment2. Ankle mobility in the current study decreased during the first year of therapy and 
remained stable in the second year, but we do not know whether improvement occurred 
after cessation of chemotherapy. It is therefore recommended to monitor mobility and 
motor performance not only during treatment but also after therapy is completed.
In conclusion, effects of the exercise programme on body composition, BMD, motor 
performance and passive ankle dorsiflexion were not beneficial over standard care. 
Low adherence to the intervention programme or adequate standard care may have in-
fluenced the results. Increased BMI and body-fat of ALL patients in the intervention group 
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recovered faster after cessation of chemotherapy, which may be due to the educational 
effect of the intervention programme. Further studies are necessary to analyse physical 
activity intervention programmes of shorter duration in order to improve adherence.
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SUMMARY
The survival rate of childhood cancer has improved tremendously over the last decennia. 
This is mainly due to the introduction of combination chemotherapy. With the improvement 
in survival, the attention for side effects has increased. One of the drugs renowned for 
it side effects is vincristine (VCR). Vincristine has proven its effectiveness in the treatment 
of acute lymphoblastic leukemia (ALL), Wilms’ tumor (WT), B-non Hodgkin lymphoma 
(B-NHL) and malignant mesenchymal tumors (MMT). However, VCR is almost invariably 
neurotoxic. The use of VCR causes a polyneuropathy with peripheral muscle weakness in 
upper and lower limbs and sensory disturbances in a ‘glove and stocking’ distribution. 
Motor performance of children receiving VCR containing chemotherapy is likely to be 
adversely affected by development of the above symptoms. The main aim of this thesis 
was to study the long-term effects of VCR containing chemotherapy on motor perfor-
mance and handwriting in children, to investigate underlying impairment (peripheral 
muscle strength and joint mobility) and other contributing factors (self-perceived motor 
competence) and to determine whether an intervention programme may diminish VCR 
induced side effects.
In Chapter 2 we investigated motor performance level in children aged 4 to12 years 
who had completed VCR containing chemotherapy for at least one year. They had been 
treated for ALL, WT, B-NHL or MMT. We found that motor performance levels varied 
greatly and were impaired in comparison to healthy peers. Surprisingly, there was no 
relationship between motor performance levels and cumulative dose of VCR, number of 
VCR administrations, or elapsed time since completion of chemotherapy. Other drugs 
that may affect motor performance are corticosteroids as they can cause myopathy. The 
effect of corticosteroids was therefore investigated. No association between cumulative 
dose of corticosteroids and motor performance was detected and corticosteroids were 
excluded as a determining factor in impairment of motor performance.
In Chapter 3 we examined the often-heard comments of parents and teachers regarding 
deteriorating hand writing skills of children treated with VCR. A standardized writing 
test was administered to children who participated in the motor performance study as 
described in Chapter 2 and attended group 4 or 5 of regular education. Both writing 
speed and quality of handwriting (i.e. legibility) were measured and compared to age 
and gender matched healthy controls. An investigator who was blinded to whether the 
writing was produced by a case or a control assessed all handwriting samples. The data 
showed that there was no difference in writing speed or quality of handwriting between 
children who had received chemotherapy and healthy peers. Cumulative VCR dose, 
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number of administrations and time since completion of VCR treatment did not affect 
handwriting skills.
In Chapter 4 a study on peripheral muscle strength and passive ankle mobility in children 
treated with VCR is reported. In the children who participated in the motor performance 
study and had completed chemotherapy at least one year previously, we measured 
muscle strength of dorsiflexors of hand and feet and also full grip and pinch grip strength, 
with a hand held dynamometer. Children attending a local school for primary education 
were invited to participate as controls.
Weakness of foot dorsiflexors produces an altered gait pattern because the ankle is not 
put through its full range of motion. Children with foot drop are at risk for developing 
a contracture of the ankle in plantigrade position. Therefore we also investigated pas-
sive ankle dorsiflexion mobility. Results showed that strength of the foot dorsiflexors was 
reduced compared to healthy peers, as was passive ankle dorsiflexion mobility. In the 
upper limb pinch grip was reduced bilaterally and wrist dorsiflexors of the non-dominant 
side were also weakened. The loss of muscle strength or ankle mobility did not fully 
explain the impaired motor performance described in Chapter 2.
In Chapter 5 we investigated children’s perceived motor competence. We examined 
how children who had been treated for cancer rated their motor performance in compari-
son to healthy peers and whether they rated themselves reliably. Children aged 8 to 12 
years from the cohort in the motor performance study described in Chapter 2, completed 
a standardised questionnaire on perceived motor competence. Survivors appeared satis-
fied with their motor performance and did not rate themselves differently in comparison 
to healthy children. However, if we took their actual motor performance scores into 
consideration they did have a tendency to overrate themselves. Also, the percentage of 
children who considered motor performance important was noticeably lower than in the 
healthy population.
As mentioned, variation in motor performance level was not related to cumulative VCR 
dose. This raised the question whether the underlying mechanism could be genetic 
variation in genes involved in VCR metabolising genes or VCR toxicity related genes. 
In Chapter 6 we further explored this hypothesis. Vincristine belongs to the group of 
vinca-alkaloid drugs metabolised by the cytochrome P450 system in the liver. Isoforms of 
this system expressed in humans are CYP3A4 and CYP3A5. Polymorphisms of CYP3A4 
exist but are rare. In contrast, CYP3A5 polymorphisms are relatively common in the 
Caucasian population. The multi drug resistance (MDR-1) gene is also involved in VCR 
pharmacokinetics. Genetic variation in the microtubule-associated protein tau (MAPT) 
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gene may influence VCR effects at tissue level. MAPT promotes the assembly and stabili-
sation of microtubules, which form a target for VCR.
We analysed whether genetic variation of CYP3A5, MDR-1 and MAPT were related 
to motor performance level of children with ALL who had been treated with the ALL-
9 protocol of the Dutch Childhood Oncology Group. The data did not provide any 
evidence that a link existed between polymorphisms in the aforementioned genes and 
impaired motor performance. However, numbers were relatively small – 34 samples 
were analysed – and not every variety in expression of CYP3A5 was present in our 
cohort. The small number also limited the power of studying the effect of combinations of 
polymorphisms in different genes.
In Chapter 7 we report on a randomised controlled trial examining the effect of an 
exercise programme during treatment for ALL on impaired motor performance, decrease 
in passive ankle dorsiflexion and bone mineral density (BMD). Children diagnosed with 
ALL were randomised into a group receiving intervention starting at diagnosis or into a 
control group receiving standard care, which includes referral to a local pediatric physio-
therapist if considered necessary by the treating physician. The intervention started with a 
pediatric physiotherapist explaining the potential side effects of chemotherapy in relation 
to motor performance. In addition an exercise programme was introduced, consisting of 
exercises to maintain hand and leg function, stretching exercises to maintain ankle dorsi-
flexion mobility and short-burst high-intensity exercises (e.g. jumping) to prevent reduction 
in BMD. Throughout the treatment for ALL children were seen at six weekly intervals to 
monitor gross motor skills and ankle mobility and also to adjust the exercise programme if 
necessary. BMD, motor performance and ankle mobility were outcome parameters. Chil-
dren were measured at diagnosis, after induction therapy (6 weeks after diagnosis) half 
way during treatment (54 weeks after diagnosis), at completion of chemotherapy (109 
weeks after diagnosis) and one year after completion of chemotherapy. The investigator 
was blinded to the randomisation.
The study showed no difference in change of motor performance, passive ankle dorsi-
flexion and BMD between ALL patients who received the exercise programme and those 
who received standard care. However, adherence to the exercise programme - reported 
by parents - was low and may have affected the results. We concluded that the exercise 
programme did not prevent motor problems and reduction in bone mass during ALL 
treatment.

ChAPTER 9
DISCUSSION AND FUTURE PROSPECTS

119
Discussion
DISCUSSION AND FUTURE PROSPECTS
The main aim of this thesis was to study the long-term effects of vincristine (VCR) contain-
ing chemotherapy on motor performance and handwriting in children, to investigate un-
derlying impairment (peripheral muscle strength and joint mobility) and other contributing 
factors (self-perceived motor competence) and to determine whether a two-year exercise 
programme as intervention may have a positive effect on outcome. In this chapter the 
results and future perspectives are discussed.
Motor performance
VCR induced polyneuropathy is a well known side effect, which sometimes leads to dose 
adjustment or even omitting of the drug 1. The occurrence of motor problems found in 
children treated for ALL has been attributed to the use of VCR 2-7. The functional outcome 
parameters used in the published series varied, making it difficult to compare results. 
Furthermore, no results on children treated with VCR for malignancies other than ALL 
were available and therefore none of the studies gave insight into motor performance of 
children who had been treated with relatively small cumulative VCR doses.
This thesis made clear that motor performance of children aged 4-12 years who had 
been treated with VCR-containing chemotherapy for ALL, WT, B-NHL and MMT was 
still impaired three years after completion of chemotherapy. This implies that the motor 
performance of these children does not recover fully and that motor problems do not only 
occur in children treated for ALL but also in other patient groups.
It was hypothesised that motor performance would depend on cumulative VCR dose and 
that children treated with the highest cumulative dose (ALL protocol with VCR/steroid 
pulses during maintenance therapy) would show poorer results, but our data did not sup-
port this. There was no difference in motor performance between children with ALL who 
had received pulses of VCR and steroids during maintenance therapy and those who had 
not. Similar results on the effect of VCR/steroid pulses were found by Reinders-Messelink 
et al 5 who tested 18 survivors of ALL and also found that the use of pulses during mainte-
nance treatment did not affect motor performance. The use of steroids may also have an 
adverse effect on motor performance as known side effects of these drugs are myopathy 
8, osteoporosis 9 and avascular necrosis (AVN) 10. Corticosteroids – prednisone and 
dexamethasone - are used in the treatment of ALL and B-NHL but not in the treatment of 
WT and MMT. However, no difference was found in motor performance scores between 
children treated with or without steroids. Differences in motor performance could there-
fore not be explained by the use of steroids.
As impaired performance was found in all patient groups and could not be related to 
cumulative dose of VCR or steroids, nor to follow up time or age at testing, interindividual 
differences in sensitivity to VCR was thought to be a possible underlying mechanism.
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Future prospects
Children in our cohort were aged 4-12 years at the time of the study and therefore rela-
tively young when receiving chemotherapy. However, AVN as a side effect of treatment 
with steroids tends to be most profound in adolescents 11,12. AVN may result in joint swell-
ing, pain, limited range of motion13 and has been shown to affect functional mobility14. 
Up to 38% of children receiving treatment for ALL have been reported to develop AVN, 
albeit often without
symptoms 10,15. Further studies that include older children are needed to investigate the 
impact of AVN on motor performance.
Although chemotherapy in our study had been completed at least one year before, a 
number of children treated with VCR still had complaints of pain and cramps in the lower 
limbs when walking a prolonged distance (data not reported). Their capacity for long-
duration activities may be affected. However, this is not measured by the movement-ABC 
as its motor tasks are short-duration activities. It would therefore need to be investigated 
separately. Peak oxygen uptake and thus fitness level was shown to be reduced in stud-
ies of ALL survivors and may be related to myocardial damage or to muscle atrophy 16. 
Future studies should explore these issues, because a reduced fitness level is known to 
have an adverse effect on quality of life17.
handwriting ability
Handwriting is a motor task and could therefore be affected by VCR polyneuropathy. 
Parents and teachers of children treated with VCR often report that the handwriting is 
difficult to read, untidy or lacking consistency 18,19. We investigated Handwriting of 
children attending group 4 or 5 of regular education who had completed VCR treatment 
more than three years before. There appeared to be no difference in writing speed or in 
quality (i.e. legibility) of handwriting compared to healthy peers. These results conflicted 
with a study using the same BHK writing test 20, which also showed that writing speed 
did not differ from matched controls, but that quality of writing was significantly lower 
5. However, those results may have been affected by the fact that children were asked 
to write as fast as possible whereas instructions of the BHK stipulate to write at normal 
speed. In addition, children had been included who were older than the BHK guidelines 
specify and the investigator was not blinded to whether handwriting had been produced 
by a case or by a control.
The results of our study raise the question why handwriting complaints are reported when 
handwriting was found to be no different from healthy peers. Reinders-Messelink reported 
that children who had been treated for ALL increased their pen-to-paper pressure when 
performing a drawing task, probably in order to compensate for VCR-related sensory 
loss 21. A significant decrease in amplitude of sensory evoked potentials of the median 
nerve, suggesting axonal injury, was found in children with ALL two years after the last 
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VCR injection 22. If neurological damage persists in the longer term it may explain the 
handwriting difficulties reported by children treated with VCR. Although children who 
have been treated with VCR apparently succeed in producing the same handwriting at 
the same speed as healthy children, they may require more effort to do so.
Future prospects
The data showed that handwriting in this cohort did not differ from healthy peers. How-
ever, as in the previous study, these children received chemotherapy at an early age. 
Whether children who received VCR when they were already skilled writers, experience 
problems is not known and warrants further investigation. The nature of handwriting dif-
ficulties in children treated with VCR has not yet been documented. Patients treated with 
VCR complain of muscle cramp in upper and lower limbs 23. Whether writer’s cramp also 
occurs in this group is not known.
Muscle strength
The research in this thesis aimed to investigate the effect of chemotherapy on motor 
performance but also to understand possible underlying mechanisms of impairment. 
Reduction of muscle strength is a known side effect of VCR polyneuropathy 1 and likely 
to adversely affect motor performance. Muscle strength had only been investigated in 
children with ALL and predominantly through performance on motor tasks 4,6. In one study 
using standardised measurements with a dynamometer chair, reduced muscle strength 
in upper and lower limbs in survivors of ALL was found 24. However, the subjects were 
adolescents and adults whose height was significantly shorter than the controls, which 
may have contributed to the reduction in strength. Using a hand held dynamometer has 
now become a wide spread method for assessment of muscle strength. Marchese et al 
found reduced strength of knee extensors and ankle dorsiflexors in eight children during 
treatment for ALL 25. Data on long-term muscle strength had not been reported.
We found evidence for long-term reduced peripheral muscle strength in lower and up-
per limbs in children treated for ALL, B-NHL, WT and MMT. No relationship between 
impaired strength and cumulative VCR dose or steroid was found. Long-term axonal 
damage due to use of VCR seems to be the underlying cause. The lack of relationship 
between level of impairment and cumulative VCR dose supports the earlier mentioned 
hypothesis of variety in sensitivity to VCR on the basis of genetic variation.
Although muscle strength was reduced in upper as well as lower limbs, only pinch 
grip strength could be related to impaired motor performance (this thesis). When test-
ing strength with a hand held dynamometer maximum generated force is measured. 
However, maximum force is not needed in the motor tasks of the movement-ABC, which 
may explain the lack of further relationships. Loss of muscle strength may prove to have a 
greater impact on long-duration activities, such as going for a walk or running.
Chapter 9
122
Passive dorsiflexion
Due to the development of VCR polyneuropathy children become unable to adequately 
lift their feet whilst walking. Heel strike is lost and a high stepping gait may even develop. 
This altered gait pattern increases the risk for a plantigrade contracture of the ankle. 
Mobility of the ankle joint is an important factor in motor performance as it affects 
walking, running and jumping. Passive ankle mobility appeared to be significantly less 
on the dominant and non-dominant side in cancer survivors treated with VCR more than 
three years after completion of chemotherapy compared to healthy peers (this thesis). 
Similar results were found in another study of ALL survivors 7. Using < 5º of passive ankle 
dorsiflexion on either side as the criterion to define impairment 26, one third of the chil-
dren in our cohort were impaired, indicating that the problem is considerable. Although 
impaired ankle mobility did not affect to motor performance score (this thesis) it may 
affect long-duration activities. Once a contracture has developed, regaining dorsiflexion 
mobility through exercise and stretching is difficult 27. Serial plaster casting or surgical 
release are other options. However, both are rather drastic measures and rarely applied. 
Prevention would appear to be the most useful strategy and was investigated in another 
study, which will be discussed later in this chapter.
Perceived motor competence
Children with physical differences are at risk for negative social perceptions and loss of 
self esteem 28,29. Athletic competence contributes to positive self-perception in children 30. 
Noll et al demonstrated lower satisfaction with athletic competence in children receiving 
chemotherapy for various childhood cancers matched to healthy class room peers 31. 
However, children were still receiving treatment at the time of the study and their lower 
satisfaction could be a reflection of low energy and chronic fatigue, which are common 
symptoms during chemotherapy. Poorer self-perception of adequacy in physical activity 
was found in children and adolescents five years after completing treatment for ALL 32. 
Neither study investigating self-perceived athletic competence reported on the relation-
ship with actual motor performance level. This was analysed in the present thesis and 
no difference was found between perceived motor competence of children who had 
completed VCR containing chemotherapy and reference values, but their actual motor 
performance scores were significantly lower. There was a weak but significant correla-
tion between perceived competence and actual motor performance scores. Interestingly, 
a large majority of the children ‘overrated’ themselves; they perceived themselves to 
function more adequately than their motor performance scores indicated. Norm values 
of perceived motor competence exist for Dutch children aged 8-12, but the relationship 
to their actual motor performance is not known. Therefore it is unknown whether healthy 
children also have a tendency to overrate. A difference with the healthy population 
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was the lower level of importance survivors attributed to motor performance (this thesis). 
Underreporting of feelings has been described in children with
cancer 33. This was explained either by use of denial or by a coping style avoiding 
conflict/feelings 34. Attributing a lower level of importance to motor performance may be 
a coping strategy in survivors of childhood cancer.
Future prospects
Investigating self-perceived motor competence in relation to actual motor performance is 
needed in order to establish whether children treated for cancer are truly satisfied with 
their motor performance, are in denial or displaying a coping strategy.
Intervention
The effect of a two-year exercise programme was investigated in a randomised study 
in children with ALL. Outcome measures were bone mineral density, body composition, 
motor performance and passive ankle mobility, of which only the latter two will be 
discussed further. On completion of chemotherapy after two years, no difference in motor 
performance or passive ankle mobility between the intervention and control group could 
be demonstrated.
The lack of difference in motor performance between the intervention and control group 
is in accordance with the results of Marchese et al. A randomised study in children on 
maintenance therapy for ALL showed that motor performance measured by time up and 
down stairs and
9 minute run-walk test had not changed compared to the control group after a four month 
period of intervention 35. Passive ankle mobility was not an outcome measure in this 
study; active ankle dorsiflexion improved in their intervention group. No deterioration in 
passive ankle mobility during treatment for ALL was shown by Wright et al 36 whereas in 
our cohort passive ankle mobility decreased significantly. Maintenance of passive ankle 
mobility as achieved in the study by Wright et al may be explained by the fact that their 
intervention was solely targeted at ankle mobility. Furthermore, only children whose pas-
sive ankle mobility decreased to < 10 degrees were required to perform the exercises. 
Both factors may have improved compliance.
In our study only 11% of the children in the intervention group had exercised daily as 
requested. Moreover, 36% had exercised less than once a week. Lack of compliance 
may have had an adverse effect on the outcome. Marchese et al also reported that 
compliance was lower than expected: children had exercised three times a week instead 
of five. However, their study showed positive results, which may be due to the fact that 
the intervention lasted for four months only and children had been involved in design-
ing their own programme. Whether the results could be maintained until completion of 
chemotherapy was not reported 35.
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Future prospects
Redesigning our exercise programme is supported by the positive results reported in 
the two aforementioned studies. Simplifying the exercises and shortening the duration 
of the intervention could be considered. Furthermore, commencing stretching exercises 
only when deterioration in ankle mobility has started to occur, may improve compliance. 
Starting exercises to improve general condition after completion of the two-year treat-
ment period may prove to be more successful than during chemotherapy when repeated 
medication tends to impede progress.
Genetic variation
Impaired motor performance was found in children treated with VCR containing chemo-
therapy and was not related to cumulative VCR, cumulative steroid dose, follow-up time 
or age at testing. Furthermore, motor performance of children treated with identical pro-
tocols varied highly. Variation in sensitivity to VCR due to genetic variation was thought to 
be the possible underlying mechanism. Vincristine belongs to the group of vinca-alkaloid 
drugs metabolised by the cytochrome P450 system in the liver. Isoforms of this system 
expressed in humans are CYP3A4 and CYP3A5. Polymorphisms of CYP3A4 exist but 
are rare. In contrast, CYP3A5 polymorphisms are relatively common in the Caucasian 
population and have been linked to the pharmacokinetics of VCR37. A recent study 
found that Afro-Americans who commonly express CYP3A5 experience significantly less 
VCR-associated neurotoxicity than Caucasians who commonly do not express functional 
CYP3A538. The multi drug resistance (MDR-1) gene is also involved in VCR pharmacoki-
netics39,40. Genetic variation in the microtubule-associated protein tau (MAPT) gene may 
influence VCR effects at tissue level as MAPT promotes the assembly and stabilisation of 
microtubules, which form a target for VCR. It was hypothesised that variation in motor 
performance in children treated with VCR, was related to the presence of polymorphisms 
in the aforementioned genes. In children who had completed treatment with the ALL-9 
protocol two years before, motor performance level appeared not to be related to the 
presence of these polymorphisms (this thesis). However, as the number of cases studied 
was relatively small the power of the study to detect single polymorphisms or combina-
tions of polymorphisms as factors contributing to motor performance disturbances was 
limited.
An alternative explanation for the variety in motor performance may be gene muta-
tions leading to an increased tendency towards hereditary neuropathies. A patient with 
Wilms’ tumor had been reported with a strong adverse response to VCR that was due to 
underlying but asymptomatic Charcot-Marie-Tooth (CMT) disease, type 1A 41. In contrast, 
a recent report described uneventful administration of VCR to a child with proven CMT 
type 1X 42. In the majority of cases however, CMT is related to a duplication of the 
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17p11.2-12 region, known as type 1A 43. Whether there is a link between this duplica-
tion and VCR related problems in children treated with chemotherapy is not yet known.
Future prospects
Large studies would be needed to analyse such genetic variations as a multifactorial 
cause of differences in motor performance. The relationship between duplication of the 
17p11.2-12 region and adverse responses to VCR warrants specific further investiga-
tion.
General conclusions and recommendations
The research described in this thesis showed that impaired motor performance in chil-
dren receiving VCR containing chemotherapy does not fully recover. Furthermore, muscle 
strength and passive ankle dorsiflexion were still found to be impaired a number of years 
after completion of chemotherapy. Although childhood cancer survivors rate their motor 
performance similarly to healthy children this may be a coping strategy.
Regular monitoring of motor performance would be beneficial in identifying children 
who develop severe disturbances during therapy and who have not made a full recovery 
after completion of chemotherapy. Intervention to prevent impairment did not prove more 
successful than standard care, but compliance was low. Prevention of reduction in ankle 
mobility seems a realistic aim and adjusting the exercise programme may prove to be 
effective. Starting exercises after chemotherapy treatment has been completed may be 
more successful in improving motor performance.
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De overlevingskansen van maligniteiten op de kinderleeftijd zijn de laatste decennia sterk 
verbeterd. Dit is met name te danken aan de introductie van chemotherapie waarbij 
diverse cytostatica in combinatie worden toegediend. Nu er een betere kans bestaat op 
overleven is de aandacht voor bijwerkingen van de chemotherapie toegenomen. Een van 
de cytostatica welke bekend is om zijn bijwerking is vincristine (VCR). Vincristine is een 
effectief middel gebleken in de behandeling van acute lymfoblastische leukemie (ALL), 
Wilms’ tumor (WT), B-non Hodgkin lymfoom (B-NHL) en maligne mesenchymale tumoren 
(MMT). Echter, bij behandeling met VCR treedt vaak neurotoxiciteit op. Gebruik van VCR 
veroorzaakt frequent een polyneuropathie, gekenmerkt door perifere krachtsvermindering 
in bovenste en onderste extremiteiten en sensorische uitval in een ‘sok en handschoen’ 
distributie. Chemotherapie die VCR bevat, heeft daarom een mogelijk negatief effect op 
de motorische ontwikkeling van kinderen.
De doelen van dit proefschrift waren enerzijds om de lange termijn effecten van VCR 
bevattende chemotherapie zowel op het motorisch prestatieniveau als op het handschrift 
van kinderen te bestuderen. Anderzijds om onderliggende oorzaken zoals verminde-
ring van spierkracht en gewrichtsmobiliteit en verdere factoren zoals zelf-waargenomen 
motorische competentie te onderzoeken. Tot slot om vast te stellen of een interventiepro-
gramma de motorische prestaties en enkelmobiliteit zou kunnen verminderen.
In Hoofdstuk 2 onderzochten wij het motorisch prestatieniveau van kinderen in de leeftijd 
van 4 tot en met 12 jaar, die waren behandeld voor ALL, WT, B-NHL of MMT. De 
chemotherapeutische behandeling was tenminste één jaar voor aanvang van de studie 
afgerond. Het motorische prestatieniveau varieerde sterk en was verminderd ten opzichte 
van de Nederlandse normwaarden. Een verassende bevinding was het ontbreken van 
een relatie tussen motorisch prestatieniveau en cumulatieve dosis VCR, aantal VCR giften, 
of de tijd verstreken sinds het afronden van de chemotherapie. Vervolgens werd daarom 
ook het effect van corticosteroïden, die gebruikt worden bij de behandeling van ALL en 
B-NHL en een myopathie kunnen veroorzaken, onderzocht. Er werd echter geen associ-
atie gevonden tussen cumulatieve dosis corticosteroïden en motorisch prestatieniveau.
In Hoofdstuk 3 inventariseerden wij de regelmatig gehoorde klacht van ouders en onder-
wijzers over een verslechterd handschrift bij kinderen die behandeld werden met VCR. 
Bij de kinderen die in groep 4 of 5 van het regulier onderwijs zaten en die hadden 
deelgenomen aan de motorische studie beschreven in Hoofdstuk 2 werd een gestan-
daardiseerde schrijftest afgenomen. De snelheid en de kwaliteit ofwel de leesbaarheid 
van het handschrift werden gemeten en vergeleken met die van het handschrift van op 
leeftijd en geslacht gematchte controle kinderen.
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Alle handschriften werden beoordeeld door dezelfde onderzoeker. Het was aan de 
onderzoeker niet bekend of het handschrift van een patiënt was, of van een controle. 
Er bleek geen verschil te zijn in schrijfsnelheid of kwaliteit van het handschrift tussen de 
patiënten en de controles. Cumulatieve VCR dosis, aantal VCR giften en verstreken tijd 
sinds het afronden van de chemotherapie hadden geen effect op de schrijfsnelheid of 
op de kwaliteit van het handschrift.
In Hoofdstuk 4 wordt een studie beschreven naar perifere spierkracht en passieve en-
kelmobiliteit bij kinderen die werden behandeld met VCR en waarbij de chemotherapie 
tenminste een jaar voor aanvang van de studie was afgerond. De data werden vergele-
ken met die van een cohort gezonde schoolkinderen.
Spierkracht van de dorsaalflexoren van voeten en dorsaalflexoren, knijpkracht en 
driepunts-knijpkracht van de handen werd gemeten met een hand-held dynamometer. 
Er werd gebruik gemaakt van de ‘break’ techniek waarbij het kind zolang mogelijk 
weerstand biedt tegen de toenemende kracht die de onderzoeker uitoefent. Verminderde 
kracht van de dorsaalflexoren van de voeten veroorzaakt een veranderd looppatroon 
waarbij een zogenaamde ‘omgekeerde’ afwikkeling van de voet optreedt. Kinderen met 
een dergelijk looppatroon lopen het risico een spitsvoet te ontwikkelen, omdat de ‘range 
of motion’ van de enkel tijdens het lopen onvolledig is. In verband hier mee werd ook de 
passieve dorsaalflexie van de enkel onderzocht, met behulp van een goniometer.
In de onderste extremiteiten bleek de kracht van de dorsaalflexoren van de voet ver-
minderd te zijn bij de kinderen die met VCR behandeld waren. In de bovenste extre-
miteiten werd verminderde kracht gevonden in de dorsaalflexoren van de pols van de 
niet-voorkeurskant en de driepuntsgreep beiderzijds. De krachtsvermindering kon de in 
Hoofdstuk 2 gerapporteerde afname in motorisch prestatieniveau echter slechts gedeel-
telijk verklaren. De passieve dorsaalflexie van de enkels bij de kinderen die met VCR 
waren behandeld was verminderd vergeleken met gezonde kinderen. De verminderde 
enkelmobiliteit had geen effect op het motorische prestatieniveau.
In Hoofdstuk 5 wordt een studie beschreven naar de zelf-waargenomen motorische 
competentie van kinderen die met VCR waren behandeld. Bovendien werd onderzocht 
in hoeverre de zelf-waargenomen competentie overeen stemde met het daadwerkelijke 
motorische prestatieniveau.
Kinderen in de leeftijd van 8 tot en met 12 die hadden deelgenomen aan de mo-
torische studie beschreven in Hoofdstuk 2, vulden een gestandaardiseerde vragenlijst 
in over zelf-waargenomen motorische competentie. De resultaten toonden aan dat de 
kinderen tevreden waren over hun motorische prestaties en dat hun zelf-waargenomen 
motorische competentie niet afweek van de Nederlandse normwaarden. Echter, als de 
zelf-waargenomen motorische competentie werd gerelateerd aan het daadwerkelijke 
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motorische prestatieniveau bleek er een neiging tot overwaardering te bestaan. Met 
andere woorden: de kinderen schatten hun motorische prestaties hoger in dan ze daad-
werkelijk waren. Tevens was het percentage kinderen dat aangaf motorische prestaties 
niet zo belangrijk te vinden aanmerkelijk lager dan in de gezonde populatie. Mogelijk 
is hier sprake van coping strategieën.
Zoals eerder genoemd, bleek het motorische prestatieniveau niet gerelateerd te zijn aan 
de cumulatieve VCR dosis. Hierdoor ontstond de vraag of er mogelijk verschillen zouden 
zijn in gevoeligheid voor VCR op basis van een onderliggende genetische variatie in 
genen betrokken bij VCR metabolisme of bij VCR toxiciteit. In Hoofdstuk 6 wordt deze 
hypothese getoetst. VCR hoort tot de vinca-alkaloïden, welke worden gemetaboliseerd 
door het cytochroom P450 systeem in de lever. Isoformen van dit systeem zijn CYP3A4 
en CYP3A5. Polymorfismen van CYP3A4 komen voor, maar zijn zeldzaam. Daarentegen 
komen CYP3A5 polymorfismen in de Kaukasische populatie frequent voor. Het multi-drug 
resistance gen (MDR-1 gen) is ook betrokken bij de farmacokinetiek van VCR. Geneti-
sche variatie in het Microtubuli-Associated Protein Tau gen (MAPT-gen) zou het effect van 
VCR op weefselniveau kunnen beïnvloeden. MAPT bevordert namelijk de constructie van 
microtubuli, welke beschadigingen oplopen door de behandeling met VCR.
Geanalyseerd werd of genetische variatie van CYP3A5, MDR-1 en MAPT een relatie 
had met het motorische prestatieniveau van kinderen die behandeld waren met het ALL-9 
protocol van de Stichting Kinderoncologie Nederland (SKION). De data toonden geen 
verband aan tussen polymorfismen in de genoemde genen en motorisch prestatieniveau. 
Echter, het aantal kinderen in de studie was beperkt en niet alle varianten van CYP3A5 
waren vertegenwoordigd in het cohort. Het aantal kinderen in de studie beperkte ook 
de mogelijkheid om het effect van combinaties van polymorfismen in diverse genen te 
analyseren.
In Hoofdstuk 7 wordt een gerandomiseerde studie beschreven naar het effect van een 
oefenprogramma tijdens de behandeling voor ALL, op het motorische prestatieniveau, 
de enkelmobiliteit en de botdichtheid. Kinderen met ALL werden na het stellen van de di-
agnose gerandomiseerd in een interventiegroep of in een controlegroep. De interventie 
bestond uit een toelichting, door een kinderfysiotherapeut betrokken bij het onderzoek 
over de te verwachten bijverschijnselen van de chemotherapie en een oefenprogramma, 
bestaande uit oefeningen om de spierkracht van de armen en benen te onderhouden, 
rekkingsoefeningen voor de enkels en springoefeningen ter verbetering van de botdicht-
heid. De kinderen uit de interventiegroep werden iedere 6 weken door de kinderfysio-
therapeut terug gezien om de motoriek en de mobiliteit van de enkels te beoordelen. 
Indien nodig kon het oefenprogramma worden aangepast. De controlegroep kreeg 
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standaardzorg, dat wil zeggen de mogelijkheid te worden verwezen naar een 1e lijns-
kinderfysiotherapeut wanneer zich motorische problemen voordeden.
De uitkomstparameters van de studie waren motorisch prestatieniveau, enkelmobiliteit en 
botdichtheid. Bij beide groepen werden metingen verricht ten tijde van de diagnose, 
na de inductie therapie (6 weken na diagnose), halverwege de behandelperiode (54 
weken na diagnose), bij het afronden van de chemotherapie (109 weken na diagnose) 
en een jaar na het afronden van de chemotherapie. De onderzoeker was geblindeerd 
voor de randomisatie. Er bleek geen verschillen te zijn in verandering in motorisch pres-
tatieniveau, passieve enkelmobiliteit en botdichtheid tussen de interventiegroep en de 
controles. De therapietrouw in de interventiegroep bleek echter gering te zijn, wat een 
negatief effect op de resultaten kan hebben gehad. Geconcludeerd werd dat afname 
van het motorisch prestatieniveau, de enkelmobiliteit en de botdichtheid niet werden 
voorkomen door het oefenprogramma.
Conclusies en aanbevelingen
Het onderzoek in dit proefschrift toont aan dat het verminderde motorische prestatieni-
veau van kinderen na afloop van behandeling met vincristine bevattende chemotherapie, 
niet volledig herstelt. Bovendien waren spierkracht en passieve enkelmobiliteit een aantal 
jaren na het beëindigen van de chemotherapie nog verminderd. Hoewel kinderen die 
werden behandeld voor kanker hun motorische prestaties na afloop van de chemothe-
rapie net zo hoog aanslaan als gezonde kinderen, is dit in de meeste gevallen niet 
overeenstemming met hun daadwerkelijk motorische prestatieniveau. Mogelijk is hier 
sprake van een ‘coping’ strategie.
Tijdens de behandeling voor ALL nemen het motorisch prestatieniveau, de enkelmobiliteit 
en de botdichtheid af. Dit kon niet worden voorkomen met een oefenprogramma. Ech-
ter, de therapietrouw was onvoldoende. Een oefenprogramma wat alleen gericht is op 
het behouden van de passieve enkelmobiliteit is mogelijk meer succesvol. Het verdient 
aanbeveling het motorische prestatieniveau en de enkelmobiliteit van kinderen tijdens de 
chemotherapie voor ALL regelmatig te evalueren. Verder wordt aanbevolen een oefen-
programma om het motorisch prestatieniveau te verbeteren te starten na afronding van 
de chemotherapeutische behandeling.
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Recent las ik in het NRC Handelsblad dat het promoveren al zo’n achthonderd jaar 
bestaat. In de 16e en 17e eeuw werden hier nog nauwelijks wetenschappelijke eisen 
aan gesteld en was het eenvoudig een kwestie van betalen. Het proefschrift werd ook 
niet noodzakelijkerwijs geschreven door de kandidaat zelf. Sinds die tijd is er echter veel 
veranderd en wordt van de kandidaat verwacht dat deze zelf onderzoek verricht. Zoals 
zo velen voor mij al hebben opgemerkt, is hierbij de hulp van anderen essentieel.
Mijn dank gaat dan ook in de eerste plaats uit naar mijn promotor. Prof. Dr. R. Pieters, 
beste Rob, tijdens de jaren van onze samenwerking heb ik heel wat gesprekken met 
je gevoerd. Geleidelijk nam mijn zelfvertrouwen toe, met name door jouw manier van 
begeleiden. Vanaf de start van het onderzoek in 2000 heb je je commentaar zonder uit-
zondering als positief en opbouwend weten te formuleren. Ik neem mijn petje daarvoor 
af en ben blij dat ik na deze promotie verder mag gaan als onderzoeker in jouw team. 
Dank voor alles wat ik van je heb geleerd.
Het onderzoek in dit proefschrift had niet kunnen worden uitgevoerd zonder de bereid-
heid van de kinderen en ouders. Hartelijk dank aan alle ouders die hun toestemming 
gaven en voor het enthousiasme en de inzet van de kinderen die hebben meegedaan. 
Bijzondere dank aan Derk Over en zijn ouders voor de toestemming voor het gebruiken 
van de foto voor de omslag van dit proefschrift.
Monique Flierman, Aad Barendregt en Karin Schrage, collega’s van de afdeling fysiothe-
rapie Erasmus MC Sophia, wil ik graag bedanken voor het behandelen van de kinderen 
die deelnamen aan de studie beschreven in hoofdstuk 7. De eisen die aan een dergelijk 
geblindeerd onderzoek worden gesteld namen jullie alle drie uiterst serieus. Dit was niet 
altijd eenvoudig omdat ik als  onderzoeker op dezelfde afdeling werk. Hierin zijn jullie 
echter zeer goed geslaagd. 
Eric Benda, hoofd afdeling fysiotherapie Erasmus MC, ik bedank je voor je steun en 
interesse in het onderzoek van start tot finish. Verder bedank ik alle andere collega’s voor 
het meedenken en het – herhaaldelijk – luisteren naar voordrachten over mijn onderzoek. 
In het bijzonder dank aan Lianne van der Giessen die altijd voor mij klaar stond om 
mee te lezen en advies te geven. Ook de collega’s van Transfergroep Rotterdam wil ik 
bedanken voor hun interesse en steun.
Zonder de hulp en medewerking van iedereen op de polikliniek kinderoncologie had 
dit onderzoek niet gerealiseerd kunnen worden. Organisatorisch vormden zij voor mij 
een belangrijke schakel.Ook Frederik Nijland in het Groene Hart ziekenhuis Gouda, 
Pieter Naterop in het Amphia ziekenhuis Breda, Harm Haas in ziekenhuis Walcheren 
locatie Vlissingen, Inge Schoonus in het Reinier de Graaf ziekenhuis Delft en Elly Meier 
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in het Ruwaard van Putten ziekenhuis Spijkenisse hebben mij allemaal hun medewerking 
verleend door te zorgen dat ik op hun afdeling kinderen kon onderzoeken, vaak meer 
dan eens. Zo ook collega’s in fysiotherapiepraktijken in Gouda, Nieuwerkerk aan de IJs-
sel en Lekkerkerk. Daardoor werden veel ouders en kinderen extra ritjes naar het Sophia 
Kinderziekenhuis bespaard, waarvoor mijn dank.
Diverse basisscholen hebben hun deuren voor mij geopend. Op de Juliana van Stolberg-
school in Kapelle, basisschool D’n Overkant in Etten-Leur en basisschool De Hoeksteen 
in Spijkenisse mocht ik in diverse groepen schrijftesten afnemen. Op basisschool Open 
Vensters in Vlaardingen en basisschool De Hoeksteen in Spijkenisse werd ik in de gele-
genheid gesteld mobiliteit en spierkracht te onderzoeken bij kinderen uit groep 3 t/m 8. 
Dat betekende voor deze scholen organisatorisch flink wat werk, niet alleen vooraf maar 
ook op de dagen dat het onderzoek werd uitgevoerd. Door iedereen werd alle mede-
werking verleend, nooit was er een bezwaar of werd het lastig gevonden. Tenminste 
niet voor zover ik heb gemerkt… De grote hoeveelheid gegevens die ik op die manier 
heb kunnen verzamelen was essentieel voor het onderzoek. Ik heb deze enthousiaste 
medewerking bijzonder gewaardeerd.
Veel dank gaat ook uit naar mijn mede-auteurs. Dr. C. van den Bos, beste Cor, hartelijk 
dank voor het meedenken, meelezen en voor het openen van de deuren van het AMC 
waar ik een gedeelte van het onderzoek mocht uitvoeren. Voor het onderzoek naar 
schrijfproblematiek was iemand nodig die bereid was 66 handschriften te beoordelen. 
Die persoon vond ik in collega kinderfysiotherapeut Nienke van Dartel. Jij ging hier 
enthousiast mee aan de slag en leverde met grote regelmaat de resultaten aan. Het zal 
af en toe een zenuwslopende taak zijn geweest, veel dank voor je hulp. 
In het kader van dit proefschrift kwam ik ook in aanraking met het begrip genetische 
variatie. Nog niet eerder had ik mij gerealiseerd dat zoveel zaken in de oncologie hier 
nauw mee zijn verweven. Dr. R. van Schaik en Dr. M.L. den Boer, beste Ron en Monique, 
jullie waren beiden goed in staat deze ingewikkelde materie voor mij als fysiotherapeut 
toegankelijk te maken. De woorden van Ron ‘dan kom je het toch gewoon nog een keer 
vragen’  en van Monique ‘zo moeilijk is het niet’ hebben er voor gezorgd dat ik het hoofd 
koel kon houden. Niettemin ben ik nog steeds onder de indruk als ik hoofdstuk 6 lees.
Bij ieder onderzoek zijn er gelukkig altijd mensen die met je mee willen denken en 
schrijven. Ik heb de bijdragen van Ilse van der Heiden, Mathilde Broekhuis, Marrit 
Meier, Robert ten Beek, Sabine de Muinck Keizer, professor Han Kemper en Marry van 
den Heuvel erg op prijs gesteld. Een aparte vermelding voor Lizet te Winkel, die samen 
met mij eerste auteur was van het artikel in hoofdstuk 6. Beste Lizet, nog niet eerder 
had ik samen met iemand een manuscript geschreven. Twee weten meer dan één is mij 
nu heel duidelijk geworden. Ik heb het als erg plezierig ervaren hoop dat hier in de 
toekomst nog  meer gelegenheid voor zal zijn. Ook je geduldige uitleg over het werken 
met GraphPad Prism, heb ik erg op prijs gesteld.
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W. Hop. Beste Wim, jouw werkwijze was weer anders en juist daardoor heb ik veel 
van je geleerd. Je enthousiasme en betrokkenheid waardeer ik zeer.   
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in Southampton you acted as my mentor. Your encouragement and enthusiasm no doubt 
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Jane, Jan and Joanna, we met during our studies 1988. Since then we have been close 
friends, you have truly become my honorary ‘sisters’. You have called me ‘Dr. Hartman’ 
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port you have shown me throughout the years. Also thanks to Ed Walsh for volunteering 
to read the entire manuscript and produce mock questions to prepare me for the real 
event.  
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uit te kunnen voeren. Ik prijs mij gelukkig dat ik in dienst ben van een organisatie met 
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Er zijn nog vele anderen die er aan hebben bijgedragen dat dit proefschrift uiteindelijk is 
voltooid. Frank Rijkee voor zijn goede zorgen, Andrea Dingemans en Astrid Schölvinck 
voor hun vriendschap en interesse. Rendie Leder en Rob Kroes meldden zich tot mijn 
groot plezier acht jaar geleden spontaan aan voor de functie van paranimf. Hun enthou-
siasme is al die tijd onveranderd gebleven ook al was de wachttijd toch tamelijk lang. 
Mijn dank gaat ook uit naar mijn naaste familie en vrienden en alle anderen die mij lief 
zijn, maar die niet met name zijn genoemd. 
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